experience patient tell story scan mark image xtend app watch video annual report experience adeline tell story scan image xtend app watch video day develop cure patientsas science drive organisation strive convert todays knowledge tomorrow therapy push boundary million people like adeline hepatitis b develop medicine help themeverywhere bring product patientswe commit bring medicine test rapidly sustainably need open new idea work collaboration healthcare system partner key resolve critical access barrier therapieseveryone benefit people needmotivate skilled employee collaborate culture location develop lifesave product share purpose abide dedication high quality ensure doctor back pioneer science treat patientsdoe patient need nextwe believe urgent deliver medical solution right noweven develop innovation future passionate transform patient live courageous decision action believe good business mean well world come work day commit scientific rigour unassailable ethic access medical innovation today build well tomorrow proud work function company world rochei feel able strengthen patient position stakeholder ike de rooijvan haaren consultant oman move basel year ago husband number ask mean son month later diagnose individual patient herpositive breast cancer fortunately receive timely treatment roche breast project mean month cancer medicine native holland team realise benefit leave young boy husband journey reallife experience patient new place sign patient consultant contract continue work roche mind undergo treatment year want roche company kindly allow participate live middle east study medicine inspire pose logistical challenge technology helps greatly mention friend work try attend meeting person possible work roche come detail broad franchise team day project aim put patient year involve prelaunch brand team effect launch postlaunch activity role change decisionmake patient perspective stage medicine team life cycle member committee set roche patient review nervous decide plunge topic team request advice patient realise share information material clinical trial experience take couple meeting brand team team get feel able strengthen patient work work breast cancer position stakeholder difficult medicine treat engage patient time make hard curious hear experience feel understand real need effort confident share opinion begin involved business team impact actual patient look way important stakeholder voice room interested strong voice work experience ike tell story scan image xtend app watch videoinnovationit dna work discipline geography drive scientific discovery redefine possible improve patient live work understanding disease differ world leader vitro diagnostic molecular level develop new business track record allow build last test medicine prevent diagnose treat meaningful partnership world disease bring patient need research academia public healthcare institution combine strength diagnostic pharmaceutical personalise healthcare found family continue hold majority strategy aim fit right treatment right voting stake company stability allow patient tradition sustainable thinking learn setback focus last value patient world large biotech company develop society remain dedicated high breakthrough medicine improve standard standard quality safety integrity legacy care oncology immunology infectious base respect individual disease ophthalmology neuroscience community world live inexperience roche scan world map xtend app watch video key figure highlight chf million drive growth group sale chf billion incremental sale medicine launch drive growth rejuvenation product portfolio chf million read core operating profit treat rare cancer chf rozlytrek approve treat rare form lung cancer occur patient dividend read chf million launch cobas pro r core investment nextgeneration integrate serum work area solution improve efficiency shorten result delivery million patient read treat roche medicine contribute sustainability roche medicine roche rank sustainable healthcare company dow jones model list essential medicine sustainability indice employee worldwide north america europe employee employee genentech south san francisco basel kaiseraugst rotkreuz switzerland roche diagnostic indianapoli mannheim penzberg germany latin america asia employee employee chugai tokyo japan africa shanghai suzhou china employees australianew zealand employee research development site manufacture site pharmaceutical pharmaceutical diagnostic worldwide diagnostic worldwide roche group headquarters manufacturing site pharmaceutical diagnostic large site base number employee sale site pharmaceutical diagnostic research development site pharmaceutical diagnostic growth rate report constant exchange rate cer average number employee express fulltime equivalent overview environment business performance community engagement science innovation integrity business access healthcare corporate governance people remuneration report material topic cover chapter cybersecurity reporting approach roche commit transparent reporting endeavour drive economic social environmental performance diligence financial performance report scope boundary material risk opportunity discuss financial non financial reporting consist annually corporate executive committee annual report finance report review audit committee board online report contain annual financial director board director statement consolidated financial statement effectiveness group risk management process non financial performance indicator cover regularly monitor group risk advisory region division roche group team overall process review externally january december financial appropriate risk management embed report scope define outlined level group pharmaceutical finance report significant diagnostic division global function conduct change scope compare formal risk assessment process year develop mitigation plan gri standard materiality material risk follow gri g guideline global reporting initiative transition read corporate governance gri standard gri guideline disclose critical impact identify longterm business sustainability activity environment society trend associate risk opportunitie economy respect conduct annual basis integrate exist materiality analysis corporate level group risk management process year emerge conduct second global materiality trend include associate risk opportunitie assessment include expert interview feedback identify internal external source stakeholder result base finding corporate sustainability www assessment feature page committee prioritise select business report report publish website sustainability trend identify trend arrochecom link technological transformation rise cyber rochecomarepdf dependency rochecomfbepdf risk management risk management policy set roche un sustainable development goal risk management approach identify analyse manage support united nations sustainable rochecomrisk report internal external risk opportunitie development goal sdgs sphere management consolidated group risk report cover corporate business strategy contribute toour reporting approach roche business sustainability trend number sdgs particularly pleased dedicated goal health sdg technological transformation goal closely connect achievement digital evolution external world help drive universal health coverage go hand technological transformation roche allow hand well access quality essential medicine develop effective tailor solution healthcare diagnostic fit perfectly vision create new market digital growth network improve save life sdgs mandate safeguard compliance integral annual reporting time accelerate enable digital innovation example contribution un goals organisation roche digital registry provide list un sdg webpage link live database digital channel ecosystem help ensure compliance transparency efficiency addition risk associate technological external assurance transformation assess manage nonfinancial reporting verify group risk management process independent party pricewaterhousecoopers ag pwc focus materiality determination rise cyber dependency process design sustainability risk era cybersecurity threat constantly opportunitie determination process rise commit security enhancement figure area safety security health personal privacy protection roche initiate bug environmental protection people contribution bounty programme partner global roche strengthen control framework review hacker community identify relevant security procedure report aspect term issue exploit nonauthorised external contribution healthcare patient organisation user addition datum privacy aspect include example new roche directive roche supplier code conduct ensure proper develop communicate respective use confidential information party internal stakeholder result figure relate grant donation sponsorship healthcare patient organisation subject reasonable assurance perform pwc limited assurance procedure prior year independent assurance report materiality assessment stakeholder engagement engage stakeholder essential build trust understand expectation embed feedback strategy daily business able jointly address common issue develop longterm solution order identify topic particularly institution peer supplier contract research relevant roche stakeholder society organisation university investor large deliver last share value conduct collect external internal stakeholder indepth materiality assessment corporate level view online survey identify key stakeholder build important press issue roche materiality analysis conduct address year add external perspective gain critical insight important final step analyse insight stakeholder consider emerge identify material topic stand trend topic highly relevant key stakeholder properly address topic align approach current goal measure approach materiality assessment performance define set indicator integratedbuilde group risk management processand inclusive design collaboratively addition materiality assessment www colleague multiple function risk share internally function charge materiality advisory human resource investor relation manage respective topic inform rochecommateriality compliance finance safety security health discussion define new corporate goal environmental protection subsequent sustainability objective key performance communication communication priority roll indicator finally outcome materiality rochecom take outcomes group risk assessment feed performance management process start point identify group risk management process key emerge trend relevance roche contribution group conduct qualitative interview process result materiality un sdgs expert broad stakeholder analysis endorse roche corporate rochecomunsdgs category include patient organisation global sustainability committeemateriality roche material topic commit deliver sustainable value stakeholder address follow material topic commitment performance material topic support un sdgs innovate patient million patient treat sustainable healthcare system commit develop medicine roche medicine availability healthcare diagnostic significantly improve billion test conduct affordability healthcare people live deliver rapid roche diagnostic product personalise healthcare broad sustainable patient access btds breakthrough therapy realworld data product designation award fda patient centricity rd efficiency roche medicine preparedness age society model list essential medicine product safety product quality trustworthy partner new partnership human right commit establish mutually pharmaceutical diagnostic ethic transparency beneficial longterm relationship partner choice accord compliance partner thirdparty survey product safety supplier critical issue product quality discontinue base audit result cybersecurity grievance human right datum privacy impact file address resolve realworld datum formal grievance mechanism provide great workplace woman key leadership role talent attraction retention commit provide work key leader diverse work organisational agility environment employee experience preparedness age society encourage build career employee engagement pursue passion protect environment improvement ecobalance energy efficiency commit minimising longterm mindset environmental impact operation decrease energy consumption use product employee decrease general waste employee deliver continue growth group sale longterm mindset commit create value core operating profit continuously stakeholder sale invest rd achieve sustainable high profitability growth rate report constant exchange rate cer average focus leadership fitting treatment patient inspire outcome matter distinctiveness way work excellence science agile network delivery setup value stakeholder build innovationour strategy roche strategy focus find new medicine diagnostic help patient live long well life evolve practice medicine guide purpose pharmaceutical diagnostic capability patient need diversity approach maximise innovation company year history longterm orientation advance field medicine bring novel treatment diagnostic patient patient delivery create value remain core reason stakeholder partner choice bringing come work day significant medical benefit patient doctor payer offer great place work employee deliver sustainable positive contribution society earn competitive return investor focus fitting treatment patient provide right therapy group people respond well right time right value inhouse combination pharmaceutical diagnostic uniquely position ultimately take people integrity courage deliver personalise healthcare develop passion difference patient internal capability build strategic people proud roche partnership ready stage personalise leadership inspire outcome matter healthcare combine insight multiple datum embrace diversity inclusion different source sophisticated analytic drive background perspective experience effective efficient research allow well entire organisation foster innovative solution therapeutic decision patient access benefit patient product critical strategy detail access plan embed business way work enable agile networked local level response everincrease pace change balancing need stability speed flexibility continue concentrate energy entirely prescription medicine vitro diagnostic setup build innovation autonomous diversify sector like generics research development centre alliance biosimilar overthecounter medicine external partner foster diversity scientific approach agility global pursuit excellence science geographical scale reach enable attract distinctiveness rest key element talent lead global science cluster exceptionally broad deep understanding bring diagnostic medicine quickly disease biology seamless integration people need dear shareholder continue significant progress effort use outstanding scientific achievement people well quality life help lead healthy life demand recently launch medicine intend use partnershipbase approach multiple sclerosis ocrevus haemophilia help resolve challenge face healthcare hemlibra particularly high system mean partner research go cancer immunotherapy tecentriq laboratory patient organisation biotech product major contributor roche company authoritie example group impressive sale growth sign framework agreement croatian chf billion government view provide personalised cancer treatment approximately approval target cancer treatment people country diagnose rozlytrek genomic test enable open disease annually globally roche work new chapter development personalise partner deliver well care patient healthcare new medicine effective tumour exhibit relatively rare progress oncology genetic change accurate pretreatment diagnosis therapeutic area able submit essential roche big core dossier new medicine second half competency come ability year risdiplam hereditary disorder spinal combine diagnostic procedure datum clinical muscular atrophy satralizumab specific practice medicine bring close goal disease central nervous system find personalise treatment option new active ingredient bring hope people patient possible eventually offer rare severely debilitate disease risdiplam effective treatment option alleviate food drug administration fda grant people symptom good case help priority review satralizumab breakthrough recovery disease therapy designationchairman shareholder letter roche gene therapy particularly promise roche innovativeness reflect net number rare disease directly address income ifrs rise substantial genetic cause condition chf billion view strong intend bolster presence substantially business performance propose area expand portfolio therapeutic active dividend chf share nonvoting ingredient acquisition gene equity security annual general meeting therapy company spark therapeutic march subject approval rd consecutive dividend increase innovation lifeimprove medicine come price interview page thank successful new launch firstclass severin schwan ceo roche group discuss development portfolio confident roche add value new treatment offer continue growth trajectory despite patient potential generate economic important medicine go patent benefit healthcare system overall like thank partner trust despite progress medicine global demand cooperation roche group employee stateoftheart diagnostic personalise tireless commitment patient wellbee treatment remain huge invest offer shareholder heartfelt thank chf billion research development trust place affinity year intend maintain record level company investment industry gratify note fda sufficiently persuade clinical benefit roche medicine award breakthrough therapy designation bring total achievement expression value new product dr christoph franz represent patient society chairman board director roche board director december paul bulcke b e g prof sir john bell e g dr christoph franz chairman c e g anita hauser e g bernard poussot c e g dr andreas oeri representative shareholder group pool voting right e g andr hoffmann vicechairman representative shareholder group pool voting right c e g dr severin schwan f dr claudia suessmuth dyckerhoff b e g julie brown b e g prof dr richard p lifton c e g prof dr hans clevers b e g corporate governance sustainability committee b audit committee c remuneration committee chairmansnomination committee e nonexecutive director f executive director g independent member board directors committee chairperson growth rate report constant exchange rate cer average important thing medicine exist severin schwan ceo roche group talk blessing new medicine price emotional moment work hear baby pia affordability switzerland people spend monthold girl belgium spinal muscular alcohol tobacco medicine atrophy sma mother finance treatment extremely expensive gene therapy crowd charge million gene therapy funding world justifiable like happen roche medicine gene therapy new field unlike conventional think commitment show pia mother therapie treatment target root wonderful important thing disorder remedy causefor lifetime medicine help daughter exist good casewith single injection remember spending time swiss current billing procedure huge sum patient organisation sma year ago fall swoop need new financing time absolutely option sma solution firmly believe need form risk parent lose child young sharing health insurer pharmaceutical age far cometwo drug company health insurer pay treat sma market treatment year case come soonthen huge blessing family long medicine prove effective way financial expenditure blessing affect access link closely benefit therapy medicine patient guarantee access yes question access crucial foremost require function insurance system contribution roche make regular contribution medicine affordable medical care guarantee patient look survey united states today affect unfortunate case develop people believe medicine country question social solidarity health cost actually similarinterview ceo roche group roche story switzerland people assume theme year annual report health insurance contribution rise patient centre mean medicine medicine actually far low personally percentage overall cost today benchmark year ago simply reduce price certainly decision ask patient interest hardly benefit patient long run company considerable financial risk order invest new medicine talk patient hear important contribution frequently continue invest research development gratitude talk patient take risk develop new well drug alive roche develop place particular drug predominantly gratitude give add motivation people emerge develop country simply afford medicine rational person moment achieve pioneer work field work affect emotionally differential pricing mean tailor price email acquaintance purchase power country question treat successfully model possible expand access medicine vital cancer drug massively china example countrie infrastructure like letter patient thank completely lack hardly life hospital doctor laboratorie country yes patient treat cancer drug thinking go medicine work alecensa receive letter behalf local partner lie foundation reasonably roche employee think proud function basic healthcare constantly impress accomplish work employee achieve field roche corporate executive committee december dr james h sabry global head pharma partner dr william pao head roche pharma research early development pre dr alan hippe chief financial officer cristina wilbur head group human resources dr severin schwan ceo roche group bill anderson ceo roche pharmaceutical dr gottlieb keller general counsel dr michael varney head genentech research early development gred barbara schdler head group communications dr thomas schinecker ceo roche diagnostic member enlarge corporate executive committee sustainable development goalbusiness performance roche business performance new product drive performance roche group dedicated longterm success new product approval strong flow positive datum clinical study demonstrate high quality pipeline material topic cover chapter longterm mindset strong result roche group significant increase number people treat new product basis strong performance group sale rise chf billion low sale herceptin mabthera core eps grow ahead sale core rituxan operating profit increase reflect strong underlying business performance ifrs net income growth japan drive recently increase impact low impairment launch product despite considerable competition intangible asset compare biosimilar continue strong uptake new medicine international region sale grow mainly successful product launch new disease area drive significant increase number provide important new treatment option patient benefit roche cancer drug people severe disease chronic condition china strong sale herceptin avastin result sale pharmaceutical division abtherarituxan increase chf billion key growth driver multiple sclerosis medicine ocrevus diagnostic division sale increase new haemophilia medicine hemlibra chf billion business area centralise cancer medicine tecentriq perjeta strong point care solution main contributor uptake medicine introduce generate growth drive immunodiagnostic chf billion growth offset business growth report asiapacific impact competition biosimilar latin america emea north mabtherarituxan herceptin europe japan america sales stable decline combine chf billion mabthera rituxan herceptin avastin estimate pharmaceutical key drug approval decline chf billion fda grant additional approval medicine commercially available sale increase led ocrevus new cancer therapy hemlibra tecentriq ocrevus sale drive tecentriq combination therapy initial treatment demand new return patient metastatic nonsquamous nonsmall cell lung biosimilar version mabtherarituxan cancer nsclc herceptin avastin launch market tecentriq combination therapy extensivestage later year small cell lung cancer essclc tecentriq combination therapy triplenegative europe sale stabilise strong demand breast cancer companion diagnostic test new medicine include ocrevus perjeta tecentriq herceptin hylecta subcutaneous injection alecensa hemlibra able offset impact treatment breast cancerbusiness performance roche kadcyla adjuvant treatment herpositive early breast cancer new cancer medicine rozlytrek lung cancer specific gene mutation solid tumour carry certain gene fusion polivy previously treat aggressive lymphoma authority eu approve hemlibra people severe haemophilia factor viii inhibitor tecentriq combination therapie initial treatment form lung cancer certain type breast cancer initial treatment nsclc small cell lung cancer quality expert roche production unit conduct multiple check medicine ensure respective production criterion meet japan rozlytrek approve treatment ntrkpositive tumour diagnostic nextgeneration system test fda clear cobas pro integrate solution new generation serum work area clinical global access program expand chemistry immunochemistry laboratory solution hiv include test mycobacterium tuberculosis design optimise laboratory operation mtb hepatitis b c hbv hcv cobas pro integrate solution laboratorie human papillomavirus hpv low middle able run test fast equipment automate income country programme disease manual task deliver result quickly aid burden high expansion global treatment decision access program highlight roche commitment make costeffective resource easily fda approve ventana pdl sp assay available people contribute companion diagnostic test help identify elimination disease region triplenegative breast cancer tnbc patient eligible great need treatment tecentriq plus chemotherapy outlook roche launch ventana dual ish dna sale expect grow low midsingle probe cocktail companion diagnostic test breast digit range constant exchange rate core earning gastric cancer patient eligible target therapy share target grow broadly line herhuman epidermal growth factor receptor sale constant exchange rate roche expect important biomarker breast gastric cancer increase dividend swiss franc growth rate report constant exchange rate cer average emea europe middle east africa immunodiagnostic drive divisional performance integrate solution broad test portfolio support precise fast treatment decision benefit patient diagnostic division continue increase sale instrument sale shipment delay regionally growth chf billion decline sale lead north america asiapacific sale increase china centralise point care solution main growth market increase sale business area major contributor divisional performance growth diabete care sale increase drive primarily drive immunodiagnostic north america sale growth mainly come business instrument launch accuchek guide product line ongoing rollout mainly china south korea sale growth partially offset decline instrument solution roche coagulation monitor north america diagnostic business improve standard patient care mean extend clinical use molecular diagnostic overall sale increase current test develop new algorithm growth underlie molecular business mean invest breakthrough clinical study growth drive blood screen digital solution clinical decision support sequence business regional growth lead asiapacific mainly china emea set new standard precision medicine roche diagnostic maintain industryleade tissue diagnostic sale stable high position continue bring market advanced sale advance stain reagent offset low integrate solution diagnostic testing laboratory efficiency clinical decision support diabetes management cobas pro integrate diagnostic solution provide design meet challenge today anticipate need tomorrow simplify shorten delivery time result complexity laboratory professional physician patient therapeutic healthcare organisation face day helping improve patient outcome rapidly change area support clinical decisionmake healthcare environmentbusiness performance roche topselling product portfolio chf million cobas immunodiagnostic cobas clinical chemistry ventana advance stain cobas blood screen accuchek diabetes care cobas system test help speed treatment decision reduce spread infectious disease cause death worldwide significantly expand range assay roche launch new test integrate core lab launch cobas system help speed treatment approval broad portfoliothe industry reduce spread tuberculosis lead comprehensiveenable clinical decisionmake cause infectious disease death worldwide personalise healthcare launch cobas mtb cobas mai test country accept cemark accelerate fda grant k clearance tuberculosis diagnosis treatment detect cobas tvmg test use cobas antimicrobial resistance high sensitivity system addition cobas tvmg test cobas mtb test enable increase detection testing menu provide flexibility process tuberculosis challenge smearnegative sample sexually transmit infection patient complete mycobacteria test menu provide sample chlamydia trachomatis ct neisseria flexibility detect combination tuberculosis gonorrhoeae ng trichomonas vaginalis tv drugresistant tuberculosis nontuberculous mycoplasma genitalium mg mycobacteria infections single patient sample growth rate report constant exchange rate cer average month launch ventana ros important approval companion sp rabbit monoclonal primary antibody diagnostic march ventana pdl sp globally vitro diagnostic ros assay gain fda approval companion immunohistochemistry ihc assay test detect diagnostic identify triplenegative breast cancer presence ros protein tissue patient eligible treatment tecentriq useful identify rospositive cancer case abraxane celgene assay launch guideline college american pathologist ce market august ventana pdl sp national comprehensive cancer network assay develop enhance visual contrast recommend ros testing confirm lung tumourinfiltrating immune cell stain adenocarcinoma case ros study triplenegative breast cancer pdl primarily number clinical trial cancer type express cell tumour cell assay primary diagnostic improve lab efficiency quality control assay tecentriq clinical development information share key benefit integrate programme tecentriq core lab april release cobas infinity prove global lab software solution new april launch ventana dual ish feature cobas infinity lab software solution dna probe cocktail companion diagnostic test instal countrieshelp ceivd country breast gastric cancer laboratory integrate wide range process patient eligible target therapy order diagnostic test actual test result important biomarker find breast gastric new cobas mobile solution offer customer cancer new assay helps drive personalise modern tablet solution interact instrument healthcare quickly deliver critical information boost efficiency convenience treatment option mobile app cobas mobicheck cobas screen share user assistance roche dialog cobas september fda approve cobas babesia mobile solution continuously enhance test use cobas system extend meet current future customer demand individual blood donation testing use blood important innovation september fda clear cobas pro babesia parasite live red blood cell integrate solution new generation serum detect traditional plasma serum sample work area solution launch approval roche wholeblood assay january country accept ce mark help healthcare professional diminish potential improve efficiency allow test risk infection transfuse blood product hour synchronised module work wholeblood testing pave way safe parallel cobas pro shorten delivery time blood supply expose previously undetectable result physician patient therapeutic red blood cellbase pathogen like babesia area support clinical decisionmakingbusiness performance roche experience advantage modern diagnosis scan image xtend app watch video immunocompromise transplant patient benefit digital transformation gain momentum cobas ebv bkv test launch approach datum healthcare digitalisation september country accept ce mark extend technology automation new test run cobas system digitalisation integration take diagnostic healthcare professional determine lab transplant patient risk complication possible year ago cause reactivation epsteinbarr ebv bk viruse system test software solutionsour integrate core lab help laboratory improve efficiency quality control information sharing support physician patient treatment decision january launch upath enterprise software board opening patient case app digital pathology offer new standard identify appropriate guideline base personalisation pathology workflow upath patient cancer type clinician select enterprise software enhance user experience intend pathway easily click digitise drastically decrease imagerendere time decision tree flowchart personalise individual integrate automate image analysis improve step specific patient pathway accessible efficiency improve workflow share tumour board participant export case pathologist upath launch follow emr electronic medical record system send release ventana dp digital slide patient submit reimbursement approval scanner payer digital tool help convert vast amount roche ge healthcare partnership healthcare datum actionable insight navify exemplify collaborative approach combine clinical decision support portfolio continue complementary expertise advance patient care grow strengthen march announce partnership play key role drive ce mark navify mutation profiler clinical future precision medicine create software annotation interpretation clinical comprehensive datadriven healthcare ecosystem report nextgeneration sequence ng test launch navify mutation improve infectious disease test access profiler navify therapy matcher optional global access program major clinical support aid help clinician link positive impact diagnose treat help clinically actionable mutation relevant therapy reduce spread hiv low middle option income country positive impact hiv diagnostic continues grow january roche ge healthcare launch add new sample type utilisation navify tumor board collaboration cobas system product partnership incorporate medical image view storage capability july expand programme patient datum enable tumour board include molecular diagnostic hiv viral load comprehensive view patient hiv hiv early infant diagnosis cobas plasma separation card mtb mtbrifinh october release navify guideline new hepatitis b c human papillomavirus app navify decision support portfolio assay run cobas app embed late national comprehensive platform testing volume need cancer network clinical practice guideline access chapter information oncology nccn guideline cover roche initiative increase access lifesave common cancer navify tumor diagnostic medicinesbusiness performance roche cobas plasma separation card support diagnosis infection virus bacteria card design simplify blood collection span early infant adult sample transportation connection count blood glucose range take picture diabete care portfolio offer collaborative accuchek active strip smartphone integrate personalised approach aim determine optimal therapy person february expand collaboration diabete risk develop disease agreement senseonic distribution eversense xl insertable continuous glucose march launch accuchek smart pix online monitor cgm sensor additional market spain portugal launches europe latin america asiapacific country plan successor region june mark placement smart pix software allow management th eversense xl sensor work multiple patient single digital diabetes mysugr mobile diabetes management app eversense solution open connectivity xl measure glucose value day noninsulindependent people type tubeless accuchek solo micropump system diabete cemarke accuchek sugarview fully integrate accuchek portfolio enable meterfree glucose monitoring launch market argentina australia launch pilot project mexico austria italy kuwait poland spain switzerland philippines nigeria app displays unite kingdombusiness performance roche woman baby good fortune maria schoedl roche germany work roche diagnostic penzberg different story diagnostic preeclampsia focus area work test marker available fate probably ironic shortly afternoon blood pressure shoot birth daughter seven preeclampsia diagnosis diagnose severe form condition early necessary step actually diagnose give understanding take avoid onset disease preeclampsia work doctor mediumsize perinatal centre suspect time lead large clinical trial condition turn critical validate diagnostic test shortterm prediction preeclampsia benefit fortunately daughter deliver caesarean measure woman suspect begin display symptom disorder test arrive clinic escape unscathed lucky apply specific criterion helpful tool easily suffer brain haemorrhage identify patient high risk develop liver failure stage severe eclampsia disease need monitor common outcome woman closely enable clinician rule baby good fortune preeclampsia woman show symptom condition day daughter deliver remember blood pressure spiked high level husband knew want doctor concern child acutely aware csection later evening thing develop preeclampsia pregnancy start spiral control begin mean highrisk patient reassure visual disturbance hardly fact well test available manage express suspicion tell immense relief especially second doctor suffer form pregnancy go specialised university hospital preeclampsia lose consciousness test marker actually start seizure doctor benefit new roche test develop get worried rule happily son bear complication complication like cerebral blee year ago continue demand new medicine increase number patient benefit innovation base roche legacy medicine new disease area uptake newly introduce medicine breast cancer strong sale growth report continue strong contribute region new indication growth sale pharmaceutical division extensivestage small cell lung cancer triple increase chf billion negative breast cancer drive sale growth new medicineskey growth driver kadcyla approve chf billion ocrevus approve chf billion treat herpositive breast cancer treatment relapse increase demand kadcyla drive rm primary progressive ppm form international region support multiple sclerosis ms people use treat patient residual disease treat ocrevus globally clinical surgery trial realworld setting datum continue consistent favourable benefitrisk profile hemlibra approve chf billion strong demand treatment indication treat people haemophilia continue addition sale increase factor viii inhibitor approve growth support launch treat people haemophilia factor viii international market inhibitor hemlibra prophylactic treatment administer subcutaneously perjeta approve chf billion multiple dose option weekly therapy herpositive breast cancer week week uptake sale grow strongly region increase strong japan europe patient demand perjeta adjuvant early breast cancer therapy support continue esbriet approve chf billion strong growth idiopathic pulmonary fibrosis sale continue expand drive growth europe tecentriq approve chf billion approve combination alecensa approve chf million target therapy andor chemotherapy treat alkpositive lung cancer alecensa form nonsmall cell nsclc small cell lung show continue strong sale growth cancer certain type metastatic urothelial cancer region europe international region pdlpositive metastatic triplenegative main driversbusiness performance roche incremental sale chf millions ocrevus neuroscience hemlibra haemophilia tecentriq oncology perjeta oncology kadcyla oncology run stringent control medicine ensure product provide patient meet respective requirement avastin oncology gazyvagazyvaro approve chf million chronic lymphocytic leukaemia cll rituximabrefractory follicular alecensa lymphoma previously untreate advanced oncology follicular lymphoma sale expand region polivy approve chf million combination therapy treatment actemraroactemra adult relapse refractory diffuse large immunology bcell lymphoma receive prior therapy fda grant accelerated approval rozlytrek approve chf million gazyvagazyvaro lung cancer specific gene mutation oncology solid tumour carry certain gene fusion rozlytrek receive approval japan lucentis ophthalmology growth rate report constant exchange rate cer average experience andy telling story scan xtend app watch video new treatment option patient speed roche bring new medicine pdl expression receive physician patient accelerate prior chemotherapy metastatic disease launch medicine make initial treatment adult essclc initial preparing launch therapy adult metastatic nonsquamous number drug candidate latestage nsclc egfrmutant alkpositive clinical development increase nsclc combination therapy firstline past year treatment adult metastatic nonsquamous nsclc people egfrmutant alkpositive ocrevusreducing risk disease progression nsclc tecentriq combination treatment indicate longerterm datum phase iii openlabel failure appropriate target therapy extension study opera opera ii oratorio show patient treat phase iii imbrave study evaluate tecentriq ocrevus continuously year combination avastin treatment people reduce risk disability progression relapse ms unresectable hepatocellular carcinoma hcc primary progressive ms result suggest receive prior systemic therapy meet early treatment ocrevus administer coprimary endpoint demonstrate twice yearly reduce risk disability progression statistically significant clinically meaningful effect sustain time improvement overall survival progressionfree survival compare standardofcare sorafenib tecentriqentere new cancer area study represent improvement overall tecentriq firstinclass medicine treat extensive survival people unresectable hcc compare stage small cell lung cancer essclc metastatic current standard care triplenegative breast cancer tnbc decade tecentriq approve additional indication multiple tumour type kadcylaimportant option breast cancer fda approve kadcyla adjuvant tecentriq combination therapy surgery treatment people herpositive early approve initial treatment essclc breast cancer residual invasive disease fda grant accelerated approval tecentriq neoadjuvant surgery treatment eu plus nabpaclitaxel treatment metastatic kadcyla approve treatment surgery pdlpositive tnbc approve tecentriq herpositive early breast cancer combination therapy initial treatment metastatic nonsquamous nsclc egfr hemlibrafor age group alk genomic tumour aberration hemlibra approve eu routine prophylaxis bleed episode people severe eu tecentriq receive additional haemophilia congenital factor viii deficiency approval patient unresectable locally fviii factor viii inhibitor hemlibra advanced metastatic tnbc tumour age groupsbusiness performance roche chf million divisional sale erivedge perjeta kadcyla gazyvagazyvaro esbriet cotellic alecensa tecentriq venclextavenclyxto ocrevus hemlibra luxturna xofluza polivy rozlytrek venclextavenclyxto sales book partner abbvie percentage sale contribution medicine launch increase steadily gazyvagazyvarobtd lupus nephritis receive prior therapy continue fda grant breakthrough therapy designation approval indication contingent btd gazyvagazyvaro adult lupus verification description clinical benefit nephritis phase ii clinical study nobility confirmatory trial gazyvagazyvaro meet primary key secondary endpoint lupus nephritis severe rozlytrekfor rare form lung cancer potentially lifethreatene disorder kidney new medicine approve treatment phase iii programme initiate metastatic nsclc japan ntrk rosntrk fda grant accelerated gazyvagazyvarocll sll approval rozlytrek treatment adult fda approve venclextavenclyxto paediatric patient year age old combination gazyvagazyvaro treatment solid tumour neurotrophic tyrosine previously untreated chronic lymphocytic receptor kinase ntrk gene fusion leukaemia cll small lymphocytic lymphoma know acquire resistance mutation sll cotellicbreakthrough therapy designation polivyaccelerate approval fda grant btd cotellic histiocytic fda grant accelerated approval polivy neoplasm harbour braf v combination bendamustine plus mabthera mutation base phase ii study rituxan treatment adult relapse adult histiocytosis mutational status refractory diffuse large bcell lymphoma demonstrate high overall response rate nextgeneration medicine continue drive treatment oncology vision loss major global health problem immunology ophthalmology neuroscience infectious latestage pipeline include project neovascular disease rare disease strong inhouse agerelate macular degeneration namd diabetic pipeline end new macular oedema dme diabetic retinopathy molecular entity clinical pipeline retinal vein occlusion faricimab bispecific pharmaceutical division number antibody design specifically eye compound nextgeneration product base phase iii trial dme namd simultaneously successful roche legacy medicine target key driver development time enter disease area progression disease pds small refillable scientific progress enable meaningful device size grain rice improvement patient continuous delivery system biologic medicine namd currently investigate oncology new medicine follow roche phase iii study strong legacy disease area include gazyva gazyvaro venclextavenclyxto recently approve infectious disease xofluza firstinclass polivy polatuzumab vedotin latestage onedose oral antiviral medicine influenza development compound include mosunetuzumab xofluza currently approve country cdtcb mosunetuzumab cdtcb treatment influenza healthy novel bispecific antibodie investigation people october xofluza blood cancer relapsedrefractory nonhodgkin antiviral medicine approve fda lymphoma drug candidate demonstrate specifically patient high risk develop compelling early datum significantly advanced complication influenza expertise develop antibody treat blood disease enter new disease area successful launch ocrevus treatment herpositive cancer perjeta kadcyla form multiple sclerosis hemlibra subcutaneous herceptin key medicine form haemophilia mark roche entry fight breast cancer follow success disease area previously focus see herceptin phase iii federica study similarly latestage development pipeline cover meet primary endpoint new investigational compound condition central fixeddose combination perjeta herceptin nervous system include spinal muscular atrophy administer subcutaneous injection combination sma neuromyelitis optica spectrum disorder intravenous chemotherapy demonstrate non nmosd autism huntington disease inferior level perjeta blood pharmacokinetic alzheimer disease compare standard intravenous infusion perjeta plus herceptin chemotherapy people risdiplam potential oral therapy herpositive early breast cancer method people sma remain drug administration significantly reduce time untreated datum dosefinde spend receive treatment pivotal firefish trial infant type business performance roche roche successfully enter new disease area provide important new treatment people severe condition include multiple sclerosis haemophilia development pipeline cover ailment central nervous system inflammatory bowel disease rare disease sma achieve key motor milestone year population give monotherapy treatment investigational molecule combination baseline immunosuppressant pivotal second sunfish study evaluate therapy fda grant breakthrough therapy risdiplam people aged year type designation satralizumab sma meet primary endpoint change baseline motor function measure scale etrolizumab large phase iii study year treatment risdiplam compare ongoing crohns disease ulcerative colitis placebo fda grant priority review main form inflammatory bowel disease risdiplam sma currently cure satralizumab undergo regulatory review roche comprehensive clinical development country nmosd rare debilitate programme investigate dose safety profile central nervous system disease datum potential clinical benefit rg people phase iii sakurastar sakurasky study suggest huntington disease programme include satralizumab efficacious treatment pivotal phase iii generation hd study option administer subcutaneously rg world large huntingtin week patient broad nmosd patient lower studybusiness performance roche go go year ago angela kiraba roche south africa remember cry work happen great britain northern ireland begin auditorium budapest hungary february correspond professor j buller empathise listen senior manager roche situation explain condition global medical affairs department word honest treatment option jump slideduchenne muscular lack thereof prognosis dystrophy dmd brother die post rare genetic disorder age orthopaedic procedure not help leg blessing think roche involve brace aid mobility bit brother dmd research divine intervention get support mother work medical affair roche south home thing get bleaker africa time thought go peace neighbour understand old brother bear disease people say curse start display sign progressive muscle avoid brother continue deteriorate weakening walking toe age lose weight eld pass away november live native kenya week bury mother take day brother fathers house second brother die july father understand empathetic distance leave barely year old remember stand mother struggle healthcare system grave take vow doctor try find wrong son graduate bachelor medicine see kind specialist able bachelor surgery work clinical practice neurologist orthopaedic year join roche surgeon nairobi finally dmd carry optimism find diagnosis information scarce treatment dmd imagine kind internet day mother hope brother research read newspaper meet people right remind day contact going go able reach muscular dystrophy group year ago refer december medium release licensing agreement sarepta therapeutics usa sustainable development goalsscience innovation roche science innovation ability capture make patient unique improve significantly pave way stage personalise healthcare convert knowledge therapy combine power advanced imaging technology artificial intelligence large database allow new insight disease material topic cover chapter patient centricity rd efficiency personalise healthcare realworld data preparedness age society patient benefit centre datum age healthcare rapidly reality stay drive continually improve ability expertise pharmaceutical diagnostic roche digitally collect aggregate curate sense forefront effort fulfil promise vast quantity diverse patient datum massive truly personalised healthcare phc generation datum add value translation processing datum deluge new insight patient datum inform meaningful datum scale help advance research development sophisticated analytic ultimately help provide todays ability glean new insight connect actionable meaningful information diverse dataset sizeable number patient continuum carefor researcher physician digitally reveal difference importantly individual patient possible unique characteristic information develop novel treatment clinical trial efficient optimise successful field indispensable clinical decisionmake engage create synergy strong innovative partner leverage roche deep inhouse link genomic profile realworld datum expertise diagnostic pharmaceutical attain deep knowledge allow company achieve progress new development help advance entire value chain development field personalise medicine delivery medicine facilitate discovery comprehensive genomic profiling lab enhance clinical trial design reveal unknown genetic anomaly accelerate approval target therapy mutational pattern drive tumour growth benefit patient second involve power large quantity curate medical data therapy outcome ability analyse unprecedented datum capture electronic health record quantitie datum new way mature point numerous patient frontier support development reach integrate set datum delivery right treatment right genomic information realworld patient right time interlink genomic clinical outcome information realworld data eg oncology use wearable sensor enable exactly foundation medicine focus granular view person disease course genetic profiling cancer flatiron health include great ability measure clinical change curate electronic medical record cancer patient eg neuroscience leverage array decide accomplish jointly start powerful partnership new technology seize acquire company roche opportunity pioneer inhouse strongly support effort continuouslyscience innovation roche digitalisation healthcare continually improve ability digitally collect curate sense vast quantity diverse patient datum translation datum ultimately help provide actionable meaningful information researcher physician importantly individual patient update deidentified datum include patient outcome clinical outcome study reveal strong datum flatiron network oncology clinic link link tumour mutational burden tmb comprehensive genomic profiling insight response cancer immunotherapy foundation medicine database rapidly grow example patient high tmb live clinicogenomic database cgdb contain twice long low intermediate link profile span tmb treat antipdpdl tumour type expect key asset immunotherapy advance development cancer therapeutic optimise design execution clinical current use cgdb involve leverage trial datum decide biomarker tmb prognostic wide range tumour type april journal american medical insight important consider association jama publish validation additional development opportunity molecule cgdb acknowledge realworld clinicogenomic plan use database datum datum obtain course routine patient source external virtual control arm care yield scientifically clinically meaningful tumouragnostic setting conduct insight correspond study randomise placebocontrolle trial include patient nonsmall cell lung cancer nsclc active experimental traditional cgdb investigate effort control arm difficult example understand genomic profile correlate rozlytrek leverage realworld datum prioritise clinical go forward realworld datum increasingly development well design trial determine building block help develop patient response good molecule underserve patient roche commit develop medicine population patient high level unmet medical need process understand current example target therapy ophthalmology outcome patient disease similar way oncology look realworld electronic advanced imaging technology new scientific health record patient insight groundbreake technology discovery platform drive development novel highly exactly roche explore personalised therapy identification specific target lung cancer include conclusive clinical endpoint distinct population different tumour mutation game change patient segment look flatiron health anonymous summarise exciting diagnostic electronic health record ten thousand lung therapeutic innovation take place field cancer patient standardofcare medication ophthalmology rd roche examine roche discover patient tumour new example discovery development mutation bad prognosis high mortality effort oncology base datum project team decide prioritise development molecule open new vistas ophthalmology target lung cancer mutation population roche focus ophthalmology development great unmet medical need transformational therapy patient major unmet medical need run risk develop potentially blind retinal disease neovascular agerelate macular degeneration sustainable development goal namd diabetic retinopathy dr diabetic macular oedema dme roche aim create safe effective new medicine diagnostic test help people rapidly grow age diabetic live long healthy life develop novel population sheer number individual medicine therapeutic area oncology eye disease result grave visual impairment blindness increase immunology infectious disease ophthalmology world antivegf molecule disease central nervous system revolutionise treatment patient pharmaceutical diagnostic division work retinal disease significant proportion rd project share research show partial improvement facility technology development vision disease benefit benefit jointly innovation approachscience innovation roche target target b monospecific fab fragment bispecific mab bispecific fab fragment eg lucentis crossmab dutafab eg faricimab new bispecific format dutafabfurther improve standard care bispecific antibody combine antigenrecognise element single construct able bind target account fact pathway root disease phc approach mean able engagement lead frequent dosing predict effectively patient respond improved longterm efficacy compare treatment enrolling trial standard care translate lean efficient clinical trial require few patient ultimately support ophthalmology programme bring solution patient short roche enter threeyear multiparty time collaboration agreement september establish insight health datum research hub addition roche strong pipeline eye health uk insight bring roche investigational molecule ophthalmology nhshdruk university hospital early late stage clinical development nongovernmental organisation technology engineer highly innovative antibody company establish data hub uk technologies accelerate research new medicine therapy technology support improve diagnosis advanced investigational medicine treatment hub gather anonymised nhs pipeline faricimab firstever bispecific antibody patient datum uk combine enter pivotal clinical trial ophthalmology unparalleled highorder retinal imaging initially dme namd develop roche focus diabete agerelate macular degeneration innovative crossmab technology generation amd dementia insight provide datum bispecific antibody develop dutafab gather certain service rapidresponse technology platform enter clinical development realworld evidence ai tool system user programme intravitreal namd dme testing industry academia fundamental april platform allow generation transformational collaboration reflect roche small extremely stable highly potent bispecific commitment establish strong network antibodie independent bind site stakeholder play active role property increase durability ocular target shape future healthcare highly personalise cell therapie cancer clear precision goal harnes vast area focus roche majority therapeutically relevant patientspecific genentech foray field cell therapy neoantigen advance generation cellular public january announcement therapie broad range solid tumour collaboration agreement adaptive ultimate vision effectively target patient biotechnologie world leader sequence tumour cell individual level pave functional profiling tcell receptor develop way development delivery manufacture commercialise tcell therapy truly personalise cell therapy patient target neoantigen long subject pioneering need research genentech neoantigen protein surface cancer cell generate tumourspecific neoantigendirecte tcell treatment new mutation present patient healthy form cancer immunotherapy fourth cell differ patient patient distinct immunotherapeutic strategy pursue clearly distinguishable normal cellular roche immunomodulator protein neoantigen recognise checkpoint inhibitor tumourtargete bispecific foreign cell person immune system antibodie personalised cancer vaccine reason consider tumour example genentech collaboration weak spot achille heel mean german biotech company biontech accessible therapeutic intervention analyse genomic sequence individual patient tumour identify promise cell produce naturally immune neoantigen fight step insert system artificially engineer genetic information encode neoantigen accurately recognise neoantigens adaptive mrnaa messenger molecule biontech biotechnologie responsible develop specifically optimise provide information innovative technology allow high throughput immune system activate combat analysis proprietary tcell sequence cancer personalise cancer vaccine work neoantigenmatching technology genentech genentech roches checkpoint inhibitors access adaptive biotechnology extensive provide effective personalise treatment option library billion neoantigentargeting patient combine approach currently tcell receptor test early clinical trial roche continue explore cell therapy meaningful path adaptive biotechnologie utilise discovery treatment patient platform identify optimal tcell receptor target patient individual neoantigen signature innovate clinical trial design harness effectively basis genentech power datum design manufacture personalise cellular meaningful datum scale realworld set medicine patient entail reshape offer tremendous opportunity improve immune system engineering individual conduct clinical trial make lean cell cell derive stem cell efficient realistic scenario receptor recognise cancer neoantigen electronic health record providescience innovation roche neoantigen infuse engineer isolate direct tcr neoantigendirecte collect blood stimulate cell engineer expand cell cell vision design manufacture personalise cellular medicine patient effectively target tumour cell individual level represent development delivery truly personalise cell therapy patient need advantage classic control arm rozlytrek approved swiftly randomise placebocontrolle clinical trial roche able choose highly innovative way realworld data rwd design registrational clinical trial main create external control arm replace reason roche departure standard way regular standardofcare arm conventional trial run clinical trial comprise control arm possible control arm standardofcare medication active arm rare disease recruitment take experimental medicine fact ros long low prevalence disease positivity occur nsclc patient rare form cancer find patient result enable trial participant enrol different trial arm daunting receive experimental medicine speed challenge addition main reason recruitment process lower trial cost enable nonparticipation clinical cancer trial fear participant treat potentially end placebo standard ofcare arm effective medicine historical standard roche decide leverage rich expedite medicine path approval rwd electronic health record flatiron screen august fda approve roche collate hundred thousand cancer rozlytrek people rospositive metastatic patient generate realworld comparator nonsmall cell lung cancer nsclc patient evidence datum possible create ntrk gene fusionpositive solid tumour external control arm eliminate concern ntrk rozlytrek tumouragnostic need enrol patient real standard control medicine mean assess approve arm lead increase trial efficiency reduce health authority base specific genetic driver delay lower cost speed lifesaving disease oral smallmolecule medicine therapy market importantly selective tyrosine kinase inhibitor design external control ensure patient receive block ros ntrk activity promote active investigational medicine start destruction correspond cancer cell eliminate concern treatment assignment datum large academic medical centre clinical trial optimisation datum community centre patient datum cgdb data realworld datum guide new treatment genomic profile deidentifie validate development selection foundation medicine plus clinicogenomic scientifically rigorous clinical datum flatiron health database demographically diverse electronic health record provide advantage classic control arm randomise placebocontrolle clinical trial realworld datum allow creation external control arm condition require replacement regular standardofcare arm order generate comparative evidence measure change eg mobility big challenge rospositive patient receive rozlytrek roche welldefine baseline measure start million patient evaluate treatment progress clinical flatiron database screen specific trial setting virtually impossible form lung cancer ros positivity end patient include analysis case angelman syndrome match patient rozlytrek neurodevelopmental disorder disease arm study design datum interest modify therapy available rare genetic regulatory body allow file approval disease affect approximately early health authority need individual devastating disease usually comparative study manifest early childhood year age main symptom severe intellectual remotely measure quality sleep rare disability lack verbal skill balance movement genetic disease problem seizure sleep impairment neurological condition difficult find relevant biomarker identify meaningful carry earlystage clinical trial endpoint allow clinician assess investigational new drug treatment therapeutic efficacy new investigational medicine angelman syndrome roche try understand confidently number neuromuscular heavily disturb sleep pattern angelman neurodevelopmental condition find meaningful patient well longitudinally capture thescience innovation roche syndrome phenotypic feature number phase affect young people place sleep mat phase ii integrate sensor mattresse subtle fast track phase iii change movement heartbeat breathing filing rate measure continually datum accelerate review sleep quality complement actigraphic phase duration device place wrist information sleep breakthrough therapy year stage rapideye movement rem nonrem etc polysomnography twice year innovative approach rd expedite review procedure hospital home visit nurse new medicine available patient early normal procedure reading eye movement heart function purpose test develop algorithm base rich dataset discern relevant pattern medical record help answer question ms patient measure sleep disruption relevant healthcare general highly fragmented lot correspond change quantify potentially relevant information patient potential improvement evaluate validate widely scatter multiple format registrie meaningful way light welldefine different source hard baseline measure ability measure sleep patient access medical record relevant neurological condition holistic meaningful way understand sleep take remote digital measurement help insight lead creation neurological condition angelman picnichealth digital healthcare company syndrome help patient collect manage medical record comprehensively blood test xray navigate complexity team partner patient owner entire medical personalise healthcare reality history document record stakeholder healthcare system picnichealth collect manage electronic work new way make sure health record user enjoy control digital transformation power datum yield health datum furthermore compile record well patient outcome different disease area thousand patient structure manner indication order expedite integrate open enormous opportunity research individualised healthcare solution roche building important new way network target partnership collaboration strong partner complementary skill roche partnership picnichealth launch set unique technological asset complexity design exactly aggregate challenge need tackled way curate valuable patient datum broaden laboratory bench doctor surgery scientific insight centrepiece roche tackle successfully collaboration picnichealth flywheelm observational study combine retrospective result large dataset analyse past seven year prospective facilitate granular understanding year go forward electronic health record ms patient treat disease people live multiple sclerosis ms experienced patient different single database nearly participant therapeutic outcome goal enrol study health record contain understand disease well ultimate aim xray lab value mri image blood test create well treatment tailor individual information comorbiditie therapeutic history need patient multiple sclerosis large dataset curate patient datum support deep understanding patient treat disease experience patient different therapeutic outcome aim create well treatment tailor individual need patientsscience innovation roche working startup bring disease management crc improve screen rate new level currently low develop country diagnostic play lead role disease challenge detect tumour early prevention management help face precancerous stage direct patient increasingly complex healthcare challenge appropriate medical followup order well evident vitro diagnostic influence approximately address specific unmet medical need third clinical decisionmake despite crc roche pilot machine learningbase accounting total healthcare clinical algorithm medilab salzburg austria spending algorithm develop medial earlysign israel risk assessment tool identify high evolve digital technology advent risk individual crc base standard digital health roche see opportunity laboratory test parameter complete blood count expand diagnostic portfolio include new digital plus patient age gender address non solution complement compliant population screen patient challenge traditional innovation approach asymptomatic act safety net roche decide seek new way cooperate people positive result follow startup bring complementary strength evaluation base clinical judgement table outofthebox thinking care provider pilot complete provide breakthrough technology novel digital tool roche experience application machine learningbase clinical algorithm roche take decision initiate private lab environment sponsor startup creasphere launch develop large hub diabete create open ecosystem digital health innovation europe end valuebase care startup participate diabetes chronic disease high week creasphere accelerator programme prevalence rate worldwide million refer batch working pilot project people affect display staggering growth roche aim develop digital rate country especially africa south health solution challenge optimise clinical east asia middle east latin america practice improve data analytic help patient individual journey roche active field pioneer innovative diabetes technology clinical artificial intelligence identify people year brand accuchek high risk crc world leader blood glucose monitor colorectal cancer crc second lead cause glucose meter test strip lance device offer cancer death death establish portfolio insulin delivery system worldwide whilst treatment option insulin pump infusion set improve decade screen tool diagnosis treatment diabete great stagnate colonoscopy gold stride recent year people diabete standard key diagnostic challenge fail reach therapeutic goal structure structured assessmenttraine therapyadapte smbg integrate personalise treatment effectiveness structure diabetes assessment documentation management ipdm personalise systematic analysis treatment significant improvement hbac high patient physician satisfaction rate increase patient adherence compare control group result integrate personalised diabetes management approach smbg selfmonitore blood glucose diabete highly complex condition extend early include numerous country difficult control manage people integration cgm datum mysugr develop diabetesrelated health roche worldleading mobile diabetes management complication early case application important step individually tailor optimal disease management approach strategy create lead open ecosystem personalised diabetes management view complexity integrate personalise solution embed fully connect diabetes management ipdm necessary data analytic platform view offer order shape advance way diabetes care outcomebase easytohandle care solution provide future roche create lead support healthcare professional bring true open ecosystem ipdm relief people diabete significant progress broad range partner expert solution provider contribute importance intellectual property innovation roche open ecosystem aim broaden roche invest fifth accelerate access well diabetes care annual sale rd follow investment globe key word context similar ratio previous year provide new connection integration integrate relevant therapy diagnostic test service people datum connect device technologie need investment basis analytic system longterm commercial success recent example roche commitment order allow continued investment drive ipdm distribution longterm patent intellectual property right insertable eversense continuous glucose monitoring provide timelimite exclusivity innovation cgm system senseonic partnership disclosure invention patent foster company announce late development new improve therapiesscience innovation roche pharmaceutical clinical pipeline fda breakthrough therapy designation grant phase phase li phase ill registration oncology inflammation immunology neuroscience infectious disease ophthalmology spark therapeutic pipeline new molecular entity cover broad range disease highly innovative technology apply create produce active moleculesscience innovation roche child wheelchair ill victoria school student switzerland year old school village annoying think nice switzerland school personal assistant walk child wheelchair help ill change shoe take coat glove give book help write bother dependent tired live spinal muscular atrophy sma help mean wait wheelchair support addition personal assistant school helper come enjoy school lot favourite subject twice month help shower german math music classmate brush tooth child sport physiotherapy session help deal different people good friend school grow help wheelchair sma year parent sister grandparent old lot fun young sister sophia year old early year operation scoliosis start kindergarten year titanium rod sma like run appointment weekly basis jealous form great team home doctor month usually instruction helps grow millimetre extend rod want maja cat home magnet little bit time afraid shy spend lot time taming soon learn hurt come close hand pet child sma like run live sma result like kid hope strength walk thing able arm not think weak grow old cure scientist try produce afraid future strange feeling medicine stabilise like parent explain sma know little improvement live day need company medicine help child play reach adult live good joyful life experience victoria tell story scan image xtend app watch video sustainable development goalsaccess healthcare roche access healthcare innovation meaningless reach need want ensure sustainable access picture stem photo competition face hope initiate roche pakistan amateur professional photographer capture emotion people recover disease care material topic cover chapter sustainable healthcare system availability healthcare affordability healthcare partnershipsthe basis success order tackle complex access challenge successfully collaboration multiple stakeholder essential roche patient heart improve access drug product acutely aware matter dow jones sustainability indices recognition innovative effective medicine effort field meaningless need unable access commit facilitate rapid addressing affordability interest patient broad sustainable access innovation multiple programme approach global scale work ensure successful treatment restrict finance order tackle complex challenge successfully essential collaborate range roche work close partnership government stakeholder focus root cause access healthcare system decisionmaker barrier roche team work improve access adjust cost help sure medicine close collaboration healthcare system affordable sustainable basis government agency patient advocacy group organisation adjustment base multiple criterion include countrys gdp gross domestic product affordability barrier access ppp purchasing power parity capita treatment look root cause public healthcare expenditure calculation lack access care consider countrys position human number different factor consider instance development index create united awareness symptom screen diagnostic nation development programme emphasise treatment capacity core barrier exist people capability ultimate form degree location criterion assess development country economic growth roche continue patient support programme progress ongoing access initiative access cancer medicine pakistanthe unmol embrace new programme concentrate programme facilitate access patient need name urdu word precious unmol proud acknowledge programme offer sustainable financial solution industry leader category strategy cancer patient pakistan averageaccess healthcare roche new diagnostic test nextgeneration medicine represent option unmet need potential increase number patient require support access therapy income capita low usd year access medicine irrespective ability healthcare make gdp pay year genentech help patient pay treatment million patient access medicine pocket genentech patient foundation provide roche wellknown cancer medicine medicine free people meet certain include programme pakistan federal financial criterion insurance government cover cost treatment insurance cover genentech medicine needy patient roche pakistan provide afford medicine year remainder treatment free charge foundation provide muchneede medication end programme benefit patient free charge approximately patient add innovation portfolio number genentech patient foundation patient need help access medicine usbased genentech member roche group likely increase plan expand committed ensure americans programme accordingly united nations development programme httphdrundporgencontenthumandevelopmentindexhdi roche support global access program aim significantly increase availability hiv testing support effort fight aid successful programme extend tackle additional infectious disease structure donation programme develop country roche participation commit work partner wfh humanitarian aid program consist healthcare sector find solution donation hemlibra funding support sustainable example effort wfh programs integrate care development training address gap care provide consistent donation substantially increase access predictable access treatment people provide prophylactic treatment haemophilia people haemophilia year country little treatment roche join european haemophilia available consortium ehc partner programme focuses sustainably improve access quality improve access diagnostic test care haemophilia b ehc partner limit access diagnostic resource lead country europe central asia spread preventable disease loss life develop country lack screen early detection february roche join world resource prevent transmission lead federation hemophilias wfh humanitarian cause death infectious disease aid program landmark initiative lead effort remedy lack access care treatment global access program establish people hereditary bleed disorder increase access diagnostic testing line withaccess healthcare roche unaid goal aim procedure prior cit framework approximately people live hiv know patient access immunotherapy disease status diagnose new framework estimate patient hiv infection receive sustain antiretroviral access threeyear period therapy receive antiretroviral therapy viral suppression roche work payer devise financial arrangement root actual outcome working collaboration global partner medicine deliverthe difference programme highly successful provide daytoday live patient access testing training healthcare worker boost capacity healthcare system combine result clinical trial realworld evidence include quality life roche expand programme include socioeconomic impact test tuberculosis hepatitis b c human combine information help payer allocate resource papillomavirus hpv lead cause cervical accord actual overall benefit treatment cancer involve collaborate clinton provide spend money health access initiative foundation hope impact innovative new diagnostic link payment agreement outcome expansion global access program aim well ensure scarce healthcare resource help meet disease elimination direct treatment effective target hepatitis cervical cancer tuberculosis example roche support local increase outcome certainty healthcare study generate datum avastin firstline treatment system lung cancer china avastin receive technical clearly understand clinical financial approval chinese national medical product outcome treatment equip healthcare administration provide chinese system way facilitate fully inform patient access decision effective way allocate resource process develop outcomebase agreement payer result flexible pricing system times successful example cancer immunotherapy cit framework belgium roche work patient access cancer belgian minister health partner help patient access effective immunotherapy immunotherapy belgium thank treatment year early collaborative effort possible standard reimbursement meeting patient need low middleincome country patient low middleincome country face initiative issue access accelerated range barrier receive vital medical care action key learning program design timely manner include implementation report outline principle disease awarenessdoe patient know good programme design highlight example contract illness successful implementation roche timely diagnosishas diagnosis launch partnership boston university early treatment effective develop project build metric funding challengesare resource available framework provide report project enable patient receive treatment report boston university access observatory publicly available database cover world health organization world publicprivate industry partnership aim bank estimate half global population improve access preventive treatment service estimate billion peopledo access low middleincome country essential health service additionally access medicine foundation estimate billion city cancer challenge ccan people access essential medicine multisector initiative support city partner organisation roche design planning implementation cancer commit address access challenge treatment solution reduce premature death range programme ncds access accelerate initiative specifically project advance citybase noncommunicable disease ncds fast oncology asuncin paraguay cali colombia grow disease low middleincome kumasi ghana yangon myanmar cities country cause extensive economic social serve combine population million hardship initial effort effective cali collaboration healthcare example ccan need assessment lead pharmaceutical company europe japan allocation usd million diagnostic north america work future equipment asuncin result live ncd access highquality adoption national cancer law treatment care mission align united nations sustainable development goal roche lead industry partner plan focus ncds universal health expand ccan initiative include city coverage view develop launchingaccess healthcare roche low middleincome country global access program support effort fight infectious disease lowincome country low middleincome country upper middleincome country ccan model upscale globally kigali perspective need assessment rwanda porto alegre brazil tbilisi georgia process focus group discussion patient city phase focus event gather information patient len mexico great petale malaysia experience cancer care service recently join ccan programme city specifically great barrier challenge access quality late ccan serve million people cancer care service engage healthcare professional mobilise local organisation currently involve need assessment generate datum patient need assessment process develop evidencebase cancer policy current city january datum point assessment collect store city ccan work civil society provide capacity realtime analysis patient organisation ensure patient voice reportingaccess healthcare roche improve supply chain result cost markup put modern cancer therapy reach ladi hameed roche nigeria good medicine little worth patient transfer patient pay reach time imagine pocket stage pay pay cent healthcare cost difference usd month dollar day reality wellknown breast cancer blood cancer nigeria primary reason medicine break suboptimal supply chain lead cost markup major change involved lead physician tell business model roche product nigeria go reluctant prescribe medicine pure marketing service company reach patient buyandsell operation meaning bring medicine take risk roche affiliate sub forex fluctuation importantly saharan africa action main supply crucial medicine hospital problem face multiple distribution pharmacy directly constantly affect level nigeria main distributor price step remove layer subdistributor subdistributor markup bring reduction finally get end user hospital price medicine immediately improve supply chain driving cost put modern cancer therapy achieve roche nigeria reach empower approach state federal government open discussion reimbursement individual complex sure patient receive distribution chain add markup therapy doctor think good cost medicine secondly start state government agree cover concern quality product treatment cost breast cancer patient cold chain weak link major discuss federal government create problem drug import directly fund critical illness number patient distributor behalf keep access roche modern medicine rise push cost mean control currency fluctuation immediately double sustainable development goalsour people roche people work support collectively sustainably create impact society building basel switzerland provide layout cafstyle table informal meeting material topic cover chapter talent attraction retention organisational agility patient centricity work help patient work roche give opportunity enhance early diagnosis disease improve health patient clear meaningful purpose people healthy workplace feel company come work day passion energy genuine interest wellbee creativity focus making truly differentiate contribution work mean share common value mean seek value roche culture serve common foundation diversity work achieve define company embody great impact survey employee value people expect workplace say treat respect dignity courage integrity passionand set high testament roche standard expectation people culture yearsa deep focus globe commitment people employee engagement feedback provide strong prepare people organisation future indicator company culture live employee believe roche great culture reality roche conduct periodic global employee purpose heartdoing opinion survey geo patient need foundation vital introduce new engagement tool partnership think prepare leverage opportunity confront glint roche employee participate challenge great confidence creativity result refer employee focus take survey ask employee fundamental question happy work roche new people practice introduce employee respond happy year ago embed employee believe work organisation important element solid accomplish roche positive impact society foundation focus agile goalsette frequent meaningful conversation number impressively high couple employee manager enable roche high degree confidence roche future adapt nimbly fastpace change prospect serve sound basis ongoing work rapidly arise opportunity include digitalisation transformation render process simple enhanced capability enable bring focused addition people work groundbreake diagnostic medicine roche share opinion company offer patient fasterour people roche find innovative solution medical need heart idea research help save life kinesis shift mindset leader general manager functional head scientific ensure new approach leadership technical leader participate good important roche second encourage leader apply readiness future ensure remain insight profoundly highly attractive employer end introduce area company support internal kinesis nearly year ago leadership selforganise agility working group development programme design shift mindset employee nominate senior leader introduce tangible approach help take programme transform roche agile organisation kinesis senior leader participate consist part programme level kinesis call synergy focuses design offer leader deep insight sustain roche transformation operate behavioural pattern senior leader include highly networked dynamic setting impact healthcare leadership development success number cervical cancer njia kiswahili path leadership development screening increase threefold compare programme way region positive feedback participant prepare leader agile way work partner programme introduce increasingly unpredictable environment india programme run collaboration ngo governmental institution tanzania change new environment require learn launch goal tackle day employee access learn cervical cancer burden country kagera region tool offer right content right format leadership development thank njias right time introduction cornerstone study nowadays spend working day deskour people roche fiveyear corporate goal woman key leadership role key leader diverse work experience employee engagement rate quartile number bracket refer quartile benchmark fiveyear goal baseline fiveyear corporate goal global learning system september pave way new approach learn fiveyear corporate goal include goal start essential training long term indicator great place work system offer modern learning technique make easy people know kind training roche conduct periodic global employee opinion survey relevant certain time evolve learn geo period set goal strategy support pilot linkedin quartile benchmark company term employee learn humu roche platform engagement fiveyear period employee provide thousand online learn resource engagement measure methodology aon hewitt employee result pilot project final year glint change glint help explore scale potential gain deep insight extensive comment possible organisation survey question frequent target pulse check key result glint survey personalise professional journey element effort adopt new mindset diversity inclusion overall corporate goal adapt change employee need focus dimension firstly goal increase number career development company operate woman key leadership position secondly increase agility flat hierarchy increase number key position incumbent experience require new approach career development develop establish region achieve new personalised career philosophy fiveyear goal gender diversity year early introduce roche focus key position incumbent diverse experience good individual require lead fulfil professional progress year fall short meeting life work common purpose overall target improve healthcare entail vary depend particular phase person life career unique interest capabilitie approach include gain experience department location roche specific project particular development programme matter individual decide forward career journey roche require healthy dose curiosity selfawareness hunger learn single day work new way advance healthcare point approval committee previously employee true self work feel early development team decide approach empower team share purpose decision need basis involve expert use collective capability expertise clearly require increase sense creativity find meaningful solution roche ownership accountability work position achieve mission bring different project quality speed new medicine diagnostic patient fast decisionmake example benefit well heart agility roche agile approach see case tecentriq triplenegative breast cancer reimagine transformation project undertake team file fda approval week pharma product development organisation instead usual case point goal bring medicine patient fast accelerate development similarly life cycle team comprise variety compromise quality expert decide future development product begin work differently attendance simplifying process consider key base need free time people acceleration instead static decision require specific topic discussion make entire process efficient easy people work different country time zone sustainable development goal new way working require expert united nations sustainable development holistic view addition deep expertise goal ensure healthy life promote open learn wellbee age important past failure willing share workplace roche support experience enable broad goal number initiative live community learn quickly build past achievement reinvent wheel campaign example hold time empower team potentially september translate theme healthy halt project devote attention priority relationship local activity fit initiative need roche employee cultural set different site project ensure roche great place work include programme devote healthy successful company strive place nutrition psychological counselling course talented people want work offer inclusive resilience aim campaign raise healthy work environment good working awareness diverse live event condition effective method deal place year site change transformationour people roche support gender parity way work create diverse inclusive culture resilience ability maintain balanced concrete effort continuously raise awareness attitude work new technology key diversity inclusion international essential element healthy sense balance women day celebrate worldwide march feel respected individuality thirty women network exist roche engage diversity ability bring one authentic self dialogue colleaguesirrespective gender work day sense strengthen topic equality diversity inclusion couple feel belong team work common purpose second global diversity inclusion week additional milestone roche commitment take commitment place work place october event include session drive innovation roche dedicate support cover mental health inclusive leadership diversity inclusion work accordance global session conduct virtually un sustainable development goal achieve gender allow roche employee participate matter equality empower woman girl roche locate week bring promote equal opportunity measure employee roche objective emphasise woman reach leadership position key step importance diversity inclusion equality future success sustainable development goalsenvironment roche environment roche seek sustainable technology minimise impact environment act photovoltaic array new car park building site kaiseraugst switzerland material topic cover chapter energy efficiency longterm mindset minimising impact ecosystem responsibility appropriate measure address press environmental issue commitment environment environmental specialist inspect facility reduce waste environmental performance implementation energy develop process environmental policy compliance business sustainable roche legal requirement internal standard process mitigate environmental risk commit monitoring performance multidisciplinary focus prevention continuously aim cover system proactive reduce cost key performance indicator increase efficiency enhance competitiveness ensure compliance high standard group safety security health environmental objective guarantee process protection department audit team equipment state art noise pollution emission water energy consumption roche ecobalance emission air water consumption landfille wasteenvironment roche solar power programme genentech member roche group organisation large corporate generator solar energy san francisco bay area develop clear define process strive reduce way minimise environmental impact set metric provide global view initiate action plan affect earth ecosystem give roche focus reduce environmental local site management freedom develop impact measure total environmental impact appropriate strategy objective curb ecobalance metric system environmental impact group ecobalance point allocate ecologically relevant parameter goal achieve product stewardship consumption energy resource sustainable construction longterm initiative emission byproduct waste significantly contribute ecobalance business activity ecobalance consider reduce environmental impact environmental parameter impact develop swiss federal office environment compliant late guideline product stewardship main contribution society deliver psp tool start new tool enable innovative diagnostic test medicine development team score improve product save improve life design performance stage product responsibility stakeholder life cycle respect important business minimise impact medicine sustainability product stewardship objective diagnostic product safety security health take ecobalance product environment entire product life stewardship score paint complete picture cycle essence product stewardship roche global sustainability impact actively support sustainability programme operation product highlight area important roche rd activity opportunity improve drug manufacturing use environmentally friendly chemical material innovative innovative product design technology help minimise roche ecological diabetes care design process engineer footprint redesign blood glucose monitoring strip meter package completely improve material outcome product stewardship improve roche efficiency reduce waste new innovative strip ecobalance development production architecture result strip size small distribution use phase product prior version few component benefit address broad range overall new design reduce polyester usage impact complement ecobalance score roche approximately tonne annum develop product stewardship performance new packaging bundle configuration improve pack density allow product ship skid tertiary container reduce distribution cost sustainable development goal environmental impact optimisation achieve reduce thickness weight roche ecompetition give employee cardboard paper product information opportunity submit idea environmental increase use recycle corrugate distribution protection activity suggestion improve component utilise packaging material certain manufacturing process certify forest stewardship council result major cost saving innovative packaging design idea include measure reduce energy cancer drug herceptin avastin consumption airconditione system come elaborate packaging protect product prove useful multiple site eighth accommodate product information typically edition competition reduce vial insert package clinic energy consumption get interest accumulate large number vial need improve logistic respect store cooler vast quantity packaging packaging transportation concept waste need disposed starting withenvironment roche development end life reuse recycle production product stewardship cycle use distribution product stewardship business process management product entire life cycle ensure product develop produce disposed responsible manner end user mind genentech engineer researcher donate excess supply time develop new generation packaging know directly repurpose genpack come size centralise supply system give local school accommodate vial single insert genentech partnership biolink package benefit clinic include low labour equipment depot nonprofit organisation dedicate cost away product packaging waste boost scientific education donate supply manage consumption packaging material equipment programme start insert genentech genpack evolve actively divert significant amount laboratory win idea submit internal sustainability supply waste landfill positively impact innovation competition local school student waste rd environmentally friendly medicine scientific research constantly evolve mabtherarituxan avastin herceptin lucentis project change end supply equipment monoclonal antibody generate large languish shelf cabinet storage proportion roche group sale belong space run item usually end waste define class active pharmaceutical ingredient stream affect ecobalance help reduce apis exempt european medicine agency waste minimise company ecological ema guideline environmental risk assessment footprint genentech host annual lab supply product low excretion rate sidewalk sale excess supply equipment judge present significant risk sewage work collect laboratory south san surface water term benign francisco campus oneday event nature constitute environmentally sustainable researcher pick supply actually compound chemical need leftover supply donate local product subject rigorous environmental school programme evolve year risk assessment sustainable construction roche commit create well workplace relevant requirement building entire benefit employee environment performance evaluate plan sustainable construction comprise structure stage end life cycle construction process occupancy process guideline group directive address energy consider economic environmental sociocultural conservation place enforce systematic aspect building life cycle employee approach improve energy performance productivity show increase building site include energy efficiency standard offer daylight well view well indoor design new equipment building air job seeker increasingly pay optimisation exist energyconsuming item attention new potential employer stance sustainability issue critical component minimise energy use sustainable construction reduce energy reduce operate energy consumption water consumption renewable energy building design way improve reflect roche ecobalance turn energy performance include high millennium roche optimise performance window extra insulation wall construction energyefficient aim ceiling door addition effective window reduce greenhouse gas ghg emission placement provide natural light reduce zero middle century need electric lighting minimise energy loss glass particular highly efficient ventilation roche standardise sustainable construction air conditioning instrumental building accordance requirement draw energy performance approach apply new clear regulation implement roche facility global organisation new specially develop software tool make possible office building south san francisco production carry construction project compliance building mannheim design provide optimal working condition operate energy standard result building award leed gold certification sustainable development goal platinum certificate respectively german society sustainable building headquarters basel waste water treat dedicated facility lead light light choice antibiotic buffer biotech efficient highefficiency fluorescent lamp remove way guarantee fit roche building reduce operating expense waste result feed directly compliance overall discharge permit ecobalance minimise river rhine case new approach ecological footprint example minimising introduce send waste water energy use innovative faade building nanofiltration unit concentrate basel triple thermal pane combine closed waste water remove cavity air integrate sunscreen reduce glare critical component comply permit help insulate interior heat coldenvironment roche total project complete avoid tonne co emission lead estimate costsave approximately chf million sustainable energy source energy efficiency building basel heated energy recover sensor workstation detect manufacturing process ground water present turn light ventilation remain constant temperature degree automatically monitor system celsius cool building summer building track energy usage approximately roche site world source energy efficiency bestknown electricity factor sustainable construction energy provider generate electricity issue critical water solar wind power circular economyin word production solar panel instal site solar panel system consumption model exist material meet percentage site total electricity product share lease reuse repair requirement rest come energy provider refurbish recycle long possible example solar panel system suzhou recent building basel site china produce electricity sunlight rubble break site mixed form cover administrative building fresh concrete concrete energy need equivalent power recycled reduce transport private household entire year need dispose concrete waste deliver roche site california successfully instal new material conserve natural resource solar array year ie gravel direct positive impact mid generate approximately roche ecological footprint gj electricity supply site electrical need case electricity source generate emit ghg positive impact roche ecobalance environmental performance datum roche measure environmental impact environmental impact employee take business ecobalance metric key metric method growth account strategic goal reduce ecofactor measure environmental ecobalance impact pollutant emission resource extraction reach target activity ecopoint unit quantity aim reduce footprint point add relate total number year ecobalance performance employee enable monitor fiveyear goal share sustainable energy ecobalance million pointsemployee energy consumption gj ffeemployee general waste kgemployee water consumption memployee goal ffe fossil fuel equivalent weight water stress change relate respectivelyenvironment roche co equivalent emission tonne ecobalance scope fuel combustion halogenate hydrocarbon emission scope air scope business flight scope direct emission generate facility scope indirect emission purchase energy scope indirect emission include scope value chain marketbase data emission air tonne voc particulate nitrogen oxides sulphur dioxide volatile organic compound halogenate hydrocarbon tonne inventory consume release global inventory include chugai genentech ventana energy consumption terajoule energy total scope scope consumption energy scope scope consumption gjemployee datum collect group gj gigajoule water usage discharge water withdraw million water consumption water consume million emission organic matter discharge waterway treatment water heavy metal discharge waterway treatment kg landfille incinerate waste tonne general waste generate landfille chemical waste generate waste contaminate soil construction waste sustainable development goalscommunity engagement roche community engagement work well build meaningful relationship mutual trust philosophy follow century deliver sustainable outcome work aftermath heavy earthquake flood nepal roche partner ngos habitat humanity help rebuild community material topic cover chapter longterm mindset availability healthcare strong partnership strong community order lasting impact roche liaise local partner assess need possible action longterm commitment provide comprehensive service community urgently need response seek achieve last little access essential healthcare improvement society main focus area service today coach train involve humanitarian social effort community clinic board equip environmental project science education pharmacy diagnostic tool diabete programme arts contemporary culture cancer screening breast examination cervical prostate cancer check train roche long history philanthropic engagement provide free primary healthcare service begin support international people rural community committee red cross year ago evolve impressive string grow remote area south last partnership accredit nongovernmental africa thabisile know impact phelophepa organisation ngos world wide fund healthcare benefit nature wwf unicef habitat humanity train boost local economy trust partner critical area high unemployment rate able offer work train community stay track year come stop permanent staff selectively develop support live work train month year implement innovative solution train provide platform experiential local partner aim simple measure learn student discipline bring last improvement study south africa sustainable impact society south african phelophepa primary healthcare train lead longestrunne publicprivate example roche transnet countrys partnerships south africa phelophepa speak main freight logistic company come volume roche unwavere commitment provide free primary healthcare rural area country train accompany nation mark th anniversary collaboration journey incredible change potentially roche renew support initiative main era bring universal healthcare external sponsor effort roche see respected partner transnet people south africa years mobile health clinic come long way recall thabisile makhaye phelophepa deliver urgently need help operation manager humble beginning sustainable way threecoach train stateoftheart primary climate change increase healthcare facility train able demand respond weather disaster primarilycommunity engagement roche support programme benefit active longterm commitment initial emergency phase partner local authority relief organisation support sustainable rebuilding effort roche sponsor development training centre help community prepare future threat cyclone idai hit mozambique zimbabwe malawi bad tropical storm affect africa response able help ngo partner donate mosquito net vital muchneede piece equipment prevent transmission malaria country longterm partner unicef journey continue thabisile makhaye phelophepa operation manager conjunction wwf support roche health clinic coach celebrate year successful partnership roche construction community disaster relief centre zimbabwe provide funding ngo actionaid roger federer foundation help rebuild preschool malawi box addition roche portugal grant funding portuguese branch red cross support people affect sustainable development goal disaster mozambique donate unit bactrim roche antibiotic emergency disaster relief effort roche employee action charity trust react partner recent effort build ongoing disaster roger federer foundation rff support relief commitment africa asia local ngo actionaid build model preschool example follow heavy rain flooding satellite preschool malawi march affect kenya partner wwf help country devastate cyclone idai fund construction disaster relief centre preschool roche support lower reach tana river follow affect provide additional funding severe flood nepal collaborate rebuild preschool damage habitat humanity build home safe area rapid unbureaucratic aid roche restore damage housing house extremely valuable allow resume complete ready service quickly possible child addition household benefit disaster resilience training local attend miss education comment janine specialist masonry course hndel ceo rff believe power education roche dedicated programme promote son family household educational opportunity young people obtain university degree opportunity world equip academic know education underestimate essential soft skill initiative prepare key say freshlyminte bachelor student thrive individual serve business administration roche main community benefactor able cover expense study family emerge market major focal point able bear financial burden eager fund education programme support talented work marketing business development student poor disadvantaged background learn practice engage sustainable local project ensure student strong employment prospect latin america collaborate fundacin graduation educacin peru colombia el salvador guatemala launch roche provide focus disadvantaged youngster fouryear scholarship talente young people india fund college university scholar lowincome family lead college ship student kiran children village university like indian south african disability literally mean scholar student great likelihood ray light kiran provide rehabilitation education find employment vocational training shine beacon light respective country live disadvantaged youngster attend university varanasi rochesponsored ask foundation recipe student generation success president fundacin educacin village high education ricardo cordero quick answer programme characterise focus concentrate find student receive scholarship good talent country active roche graduate maharishi institute school focus attention johannesburg student set need economy country graduate institute nonprofit question solely sponsor economics business organisation aim educate new administration student thank highly generation leader south africa provide motivated dedicated team able offer truly fund student look access education tailormade highly sustainable programme offer educational partner future employment prospect graduate give community maharishi prove highly successful leave set scholarship apart lasting impact student program compromiso de honor principle family community scholar finish study expect repay scholarship provide year graduate nkulumo dlamini financial mean real contract soweto township johannesburg young simple oath graduate happy socommunity engagement roche bright future ahead batch rochesponsored students maharishi institute johannesburg graduated foundation foster active alumnus career start enterprise see scholar network say ricardo way succeed aim continuously grow programme promote networking scholar alumni thank roche strategic partner actively stay contact gradually want know happen year scholarship worthwhile science technology core adjust programme necessary business support international local programme spark interest roche initially provide scholarship student discipline young people europe fundacin educacin graduate number science education initiative follow remainder support swiss youth science complete study ensure year found sponsor continuity company commit international swiss talent forum think tank year sponsor scholar roche student world begin contribute foundation ongoing istf highly talented young success story president describe people different country participate direct impact scholarship family programme genentech run community obvious futurelab cooperation local school district invisible scholar serve role inspire young student explore career science model young student technology engineering mathematic sustainable development goalsintegrity business roche integrity business working integrity professional virtue ask employee matter culture ensure manufacturing process finish product meet strict regulatory requirement set authority material topic cover chapter human right ethic transparency realworld data product quality patient centricity datum privacy compliance respect human right company influence happen employee value chain customer local community long run successful respect human right view simply business act integrity trust respect matter compliance roche take everyday operation go far step aim avoid harm comply mandatory requirement deliver meaningful positive outcome make positive impact society stakeholder endeavour subject vital importance operation worldwide human rightsa topic number recent example roche foster globally business roche work partner embed human right daily business pharmaceutical state code conduct support site shanghai china example run respect human right implement finance programme small minorityowne un guiding principle business human innovative supplier need fund right building protect respect remedy foster supplier diversity give well framework develop harvard professor john access innovation small agile ruggie equally commit un company global compact principle universal declaration human right fundamental labour site basel rotkreuz switzerland right stipulate international labour penzberg germany collaborate organization declaration fundamental party employ disabled people fully principle right work integrate daytoday work support manufacturing supply chain activity ask affiliate talk human compliance right achievement provide employee roche group speakup line available transparency corporate action language country chief compliance officer receive report strengthen relationship stakeholder allege violation code conduct business ethic incident reporting system unfounded founded jointly improve human right standard investigation result employment contract agreement business work pharmaceutical partner terminate ground unethical behaviour supply chain initiative psci revise auditintegrity business roche programme create robust process identification human right violation implement risk management programme design systematically identify assess mitigate adequately manage risk human right violation programme apply operation value chain businessrelate activity identify main human right risk area data privacy safety workplace working condition employee representation publish guideline httpsgorochecomduediligenceprocess provide overview develop implement adequate duediligence process foster inclusion employee disability helps identify assess potential impact risk relate human right roche group supplier sustainability assurance visit major finding area working condition include excessive overtime unsatisfactory compensation overtime insufficient rest day working week inadequate payment sustainable development goal social benefit conduct supplier sustainability assurance visit result finding roche global procurement organisation minor issue lack develop method identify write safety health policy employee corrective risk human right violation global action plan implement supplier supply base perform site visit sure supplier identify roche continue assess mitigate risk risk protect human right human right violation enhanced human discover human right right violation risk process identify risk labour issue critical supplier provider receive report critical finding supplier find evidence child labour supplier modern slavery philipp aerni global business local culture springer psci group pharmaceutical company dedicate establish promote responsible corporate practice manage safety quality culture roche philosophy health safety key principle roche strategy tab employee valuable resource roche mental health risk involve level prevention commit promote safe healthy workplace primary secondary tertiary core element environment employee establish strategy roche health protection directive maintain safe working practice proper separate section dedicate primary prevention procedure direction safety everyone respon mental health problem workplace primary sibility rest level management prevention design monitor risk factor employee result safety datum show cause stress relate work mark improvement compare year work environment social setting graph despite effort employee die company event profoundly regret secondary tertiary prevention organise tragic accident offer sincere accord local need responsibility condolence victim family friend local human resource safety security health environment officer medical service monitor mental health risk management depend site organise digitalisation globalisation substantial workload secondary prevention measure aim job insecurity new hallmark modern personal capability cope stress example workplace characteristic identify time management course resilience training help main source workrelate stress potential employee manage individual stress level mental strain affect employee health aim tertiary prevention minimise impact exist mental health problem individual counselling employee health safety roche site mental health strategy place tackle issue drive forward aid implementation headquarters develop starter pack guideline social medium exchange experience site furthermore mental health workshop hold roche site mississauga canada singapore april november respectively attract participant site north america apac region main focus workshop prevention mental health problem group participant give opportunity conduct risk assessment mock goal work situation mental health continue play losttime illness rate roche accident rate important role roche continue offer losttime accident rate number workrelate accident everimprove healthy working environment working day lose year accident threeyear average employeesintegrity business roche quality engraine culture provision highquality product patient time represent foundation approach manufacturing operation quality everyone responsibility believe quality culture form attitude action single person global manufacturing community believe constant nurturing development quality culture great priority seek accelerate delivery medicine patient continue encourage people look opportunity strengthen quality aspect manufacturing environment focus safeguard highquality supply patient example colleague base kaiseraugst site switzerland propose move quality assurance team discrete area operate manufacturing line result well contribution healthcare patient organisation integration production operation simple incremental change dedicate engage transparent dialogue healthcare patient increase number visual support organisation grant donation patient organisation total board shop floor help support chf million healthcare organisation chf million sponsorship people fully understand new process healthcare patient organisation total chf million detail find website rochecomperformance see successful conclusion manufacture quality work plana multiyear journey succeed address car safety technical improvement entire manufacturing network example indianapoli safety fleet team join force tackle driver safety corrective preventive action system new vehicle equip safety feature forward collision introduce disciplined review performance warn emergency brake blindspot detection function car safety statistic metric improve sample management add safety feature reduce number report car crash laboratory control system approximately team look bring change behaviour sale representative drive consider risky dangerous spirit initiative continue monitor telemetric solution monitor harsh acceleration corner brake quality compliance sustainability plan speed wear seat belt furthermore driver require attend seek reinforce change eighthour training course entitle wheel programme drive search opportunity infancy roche indianapoli record drop number car improvement crash democratise health datum datadriven healthcare potential transform regulation gdpr roche building health system improve outcome patient considerable datum protection expertise gain healthcare sustainable unlock decade conduct thousand potential health datum need accessible clinical trial involve million patient share consequently datum privacy protection globe legitimate concern important strike balance protect personal datum instance transparency privacy core datum benefit society balance partnership picnichealth aim transparency foundation datadriven collaboration translate valuable information healthcare system trust citizen capture patient individual medical record support different stakeholder datum standardise research purpose new approach datum share patient put patient centre provide service allow access continue respect preferred aggregated medical record support partner trust data care consent research programme protection responsible use personal datum free common barrier research participation reflect daily operation anchor roche group code conduct endorse harnessing power datum position paper access use realworld collaborate lead company datum rwd roche complie applicable field genomics rwd foundation datum privacy law include swiss datum protection medicine flatiron health building act european union general data protection strategic partnership develop new target diagnostic therapy help improve decision making patient journey example strategic collaboration sustainable development goal ge healthcare combine complementary expertise diagnostic develop crosssector collaboration clinical decision support solution oncology establish michael j fox foundation acute care help healthcare professional navigate parkinson research mjff june increasingly complex medical practice roche provide digital confident decision timely fashion biomarker platform study fund roche drive crosssector collaboration mjff crosssector consortium industry academia research aid mobile tool data parkinson organisation societal benefit disease affect patient life day collaboration significant people diverse capture aim adopt unified background come share idea high biomarker approach board quality datum work accelerate innovation parkinson research development area healthcareintegrity business roche roughly citizen willing share health datum research security privacy guarantee advance regulatory framework rwd essential clinical development rwd allow regulator inform rozlytrek study feasible decision safety efficacy value medicine include comparator arm rarity diagnostic patient group condition study develop external control arm flatiron roche working authority understand data patient undergo standardofcare well use rwd support approval vitro treatment comparative realworld datum diagnostic new medicine regulate digital successfully file japan health product example roche flatiron great example make research efficient health crossindustry collaboration provide well option participant fast establish dukemargolis center health policy aim collaboration advance policy development relate regulatory acceptability rwd united states fdas software precert pilot program roche engage diagnostic tech industry leader develop novel digital health regulatory framework speed product access policy maintain safety effectiveness come health datum topic relate innovation access agency fda ask industry personalise healthcare engage public policy stakeholder fundamental forward bestpractice example rwd aspect good public governance strive strengthen stakeholder utilise regulatory submission example understand ofand trust inour business convince constructive influenza medicine xofluza fda form lobby interest party involve society require additional toxicology study rwd roche remain independent political affiliation appropriate roche million tamiflu patient roche disclose contribution sign transparency register public authority able repeat use medicine information find public policy webpage spend pose risk datum accept fda chf million switzerland include payment industry association additional safety study conduct chamber commerce financial assistance trade union donation consequently rwd save crucial year political party cantonal federal level donation political party clinical development xofluza available low doubledigit thousand range swiss franc account patient fast approximately total contribution donation european commission result public consultation transformation health care digital single marketintegrity business roche patient want consider partner decision use data noga levin picnichealth usa company bear experience patient want consider partner patient diagnose crohns disease decision use datum healthcare system extremely fragmented expectation watch tv show datum fundamentally belong patient doctor charge set infrastructure process rely know go reality patient aware charge care datum research purpose person actually step want system go appointment long run need sure patient consent right thing inspire set picnichealth good outcome research avoid app develop dedicated compile electronic create antagonistic dynamic patient feel health record make available patient trick fully scientific community authorise understand datum patient app work collect manage available health record take patient want research happen want medical record picnichealth well care disease new treatment organise datum personal health record big challenge get initial hurdle discomfort patient actually people sensitive personal datum big company datum ecosystem everybody want personal datum give rise feeling outside care control turn need engage overwhelming need patient able contribute patient equal partner big picturefor research improve care objection use datum realise make sense generate datum mainly connection nontransparent way real world order understand disease well find work transparent patient get able use transparency issue consent receive overwhelming support travesty material topic cover chapter compliancecorporate governance roche corporate governance strong board director highly skilled manager act integrity essential wellfunctioning governance roche report set structure process rule roche take basis good governance company principle business activity focus sustainable value corporate governance requirement particular creation innovation management culture applicable law swiss stock exchange conform recognise standard good corporate swiss exchange directive swiss code governance policy transparent communication good practice corporate governance promulgate embody roche corporate governance principle swiss business federation economiesuisse build basis successful implementation company internal governance framework roche commitment serve stakeholder particularly article incorporation bylaw embody principle need ensure strong board director represent company business manage supervised interest shareholder manner consistent good corporate governance stakeholder highly skilled manager include necessary check balance act integrity extremely important print annual report contain select link recognise consecutive roche website httpswwwrochecom reader year sustainable company provide snapshot pharmaceutical index dow jones sustainability company report date direct index djsi roche rank second djsi source consult time base indepth analysis economic uptodate information corporate governance social environmental performance djsi roche annual report cover single serve benchmark investor integrate financial year end december website sustainability consideration portfolio contain information permanent nature sustainability core business practice late roche news company article award reflect commitment run incorporation bylaw curricula vitae business way ethical responsible current status end term create longterm value stakeholder report date december year year member board corporate governance report set director corporate executive committee structure process rule roche take publish website basis wellfunctione corporate governance roche complie relevant detail refer follow report httpswwwrochecomaboutgovernancehtmcorporate governance roche annual general meeting annual general meeting board director board committee board director chairman nomination committee board committees remuneration committee audit committee corporate governance sustainability committee corporate executive corporate executive committee ceo ceo ceo general committee cfo hr roche group pharmaceutical diagnostic counsel enlarge corporate executive enlarge corporate executive committee committee gre pre partnering communication board director st annual general meeting agm roche organising meeting immediately follow hold ltd march shareholder reelect agm board director determine dr christoph franz chairman board structure composition remain director committee show page board director corporate furthermore agm reelect andr hoffmann executive committee prof sir john bell julie brown paul bulcke anita hauser prof dr richard p lifton dr andreas oeri peter voser serve member board bernard poussot dr severin schwan dr claudia directors roche holding ltd step suessmuth dyckerhoff peter r voser elect member board director roche prof dr hans clever additional new member end june additional role board director term year interim ceo abb provide article incorporation march forthcoming agm addition agm elect dr christoph franz board director nominate chairman andr hoffmann prof dr richard p lifton bernard exception dr andreas oeri prof sir poussot peter r voser member john bell remaining member board remuneration committee director reelection july roche announce dr andreas oeri year board director nominate term office inform board directors dr christoph franz andr hoffmann stand reelection member prof dr richard p lifton bernard poussot board director agm reelection member remuneration dr jrg duschmal fifthgeneration descendant committee agm founder roche confirm interest standing election member board bdo ag resignation july directors board director independent proxy elect agm propose dr jrg duschmal new representative view cease execution mandate shareholder group pool voting right independent proxy pursuant article para election board director agm ordinance excessive compensation list jointstock company vegv board year service board prof sir john directors appoint testaris ag replacement bell decide stand reelection independent proxy conclusion board director agm board agm board director nominate testaris director propose addition dr patrick frost ag election independent proxy agm ceo swiss life group election board period conclusion director agm ordinary agm shareholder board director board committees board director chairman nomination committee board committees remuneration committee audit committee corporate governance sustainability committeecorporate governance roche composition year birth elect board director dr christoph franz c e g chairman andr hoffmann representative c e g vicechairman shareholder group pool voting right dr andreas oeri representative e g shareholder group pool voting right prof sir john bell e g julie brown b e g paul bulcke b e g prof dr hans clevers b e g anita hauser e g prof dr richard p lifton c e g bernard poussot c e g dr severin schwan f dr claudia suessmuth dyckerhoff b e g secretary dr gottlieb keller board director honorary chairman dr fritz gerber board directors curricula vitae cvs member board director current member httpswwwrochecomaboutgovernanceboardofdirectorshtm b member year httpswwwrochecomaboutgovernanceecbodformerhtm c information cvs report date december year year httpswwwrochecomaboutgovernancearchivformercvshtm corporate governance sustainability committee b audit committee c remuneration committee chairmansnomination committee e nonexecutive director f executive director g independent member board directors committee chairperson corporate executive committee william bill anderson ceo genen tech dr michael heuer assume ad interim appoint ceo roche pharmaceutical effective leadership roche diagnostic division january new member corporate member corporate executive executive committee report dr severin committee effective october retire schwan ceo roche group predecessor daniel plan end july oday step role ceo roche pharmaceutical member corporate board director appoint dr thomas executive committee december prior schinecker head diagnostic business assume new responsibility outside roche area centralise point care solution ceo provide support ensure smooth transition roche diagnostic member corporate activity end february executive committee effect august dr stephan feldhaus head group communication director appoint claudia bckstiegel member roche enlarge corporate executive currently head legal diagnostic division committee decide continue career outside position general counsel join company end september barbara enlarge corporate executive committee report schdler head communication public dr severin schwan april parallel affairs eon se succeed october dr annette luther currently general manager head group communication member roche diagnostic international ltd rotkreuz roche enlarge corporate executive committee switzerland secretary board reporting ceo roche group dr severin director report dr christoph franz schwan information member corporate dr gottlieb keller general counsel member executive committee enlarge corporate corporate executive committee secretary executive committee list page board director retire year board director corporate roche end march board executive committee corporate executive corporate executive committee ceo ceo ceo general committee cfo hr roche group pharmaceutical diagnostic counsel enlarge corporate executive enlarge corporate executive committee committee gre pre partnering communication composition year birth position corporate executive dr severin schwan ceo roche group committee bill anderson ceo roche pharmaceutical dr thomas schinecker ceo roche diagnostic dr alan hippe chief financial officer cristina wilbur head group human resources dr gottlieb keller general counsel enlarge corporate dr michael varney head genentech research executive committee early development gre dr william pao head roche pharma research early development pre dr james h sabry global head pharma partner barbara schdler head group communication secretary corporate perolof attinger executive committee statutory auditor kpmg klynveld peat marwick goerdeler sa reporting year roche holding ltd kpmg ag auditor charge john morris ian starkey mark baillache business year chief compliance officer dr urs jaisli september pascale schmidt october curricula vitae cvs member corporate executive enlarge corporate executive committee current member httpswwwrochecomaboutgovernanceexecutivecommitteehtm b member year httpswwwrochecomaboutgovernanceecbodformerhtm c information cvs report date december year year httpswwwrochecomaboutgovernancearchivformercvshtmcorporate governance roche dr andreas oeri chairman corporate governance sustainability committee andr hoffmann chairman remuneration committee group structure shareholder roche operate business organise integrate roche pharmaceutical division pharmaceutical diagnostic diagnostic division consist follow pharmaceutical division comprise business business area centralise point care segment roche pharmaceutical chugai solution molecular diagnostic tissue diagnostic genentech segment diabetes care roche pharmaceutical incl genentech pharmaceutical chugai centralised point care solution molecular diagnostic diagnostic tissue diagnostic composition diabetes care www business activity carry group andr hoffmann vicechairman board exchange subsidiary associate company detailed director chairman remuneration regulation information roche holding ltd significant committee dr andreas oeri member httpswwwsix subsidiary associate company include board director chairman board exchange company list information domicile share corporate governance sustainability committee regulationcoman capital equity interest list finance serve respective capacity board homepublication report note roche group consolidate committee representative shareholder significant financial statement list subsidiary group pool voting right receive shareholdershtml associate remuneration set forth remuneration report finance report note major shareholder list finance report roche group consolidated financial statement note roche group consolidate relate party relationship financial statement equity attributable roche exist shareholder pool voting right shareholder relate party page note financial statement roche crossshareholding hold ltd significant shareholder addition significant shareholder publish relevant webpage disclosure office exchange regulation capital structure information roche capital structure provide form share capital confer voting finance report note financial right ne confer right statement roche holding ltd share participate available earning additional detail contain article liquidation proceed follow repayment share incorporation roche hold capital roche ne right pertain thereto include provision protect interest movement recognise amount ne holder describe article financial year detailed finance report incorporation roche holding ltd note financial statement roche holding ltd information debt instrument issue outstanding bond provide company share capital chf finance report note roche group divide fully pay bearer share consolidate financial statement debt nominal value chf restriction exercise vote right information employee stock option provide share deposit share vote finance report note roche group restriction consolidate financial statement equity compensation plan include detailed authorise conditional capital information stocksettle stock appreciation right ssar plan restrict stock unit addition nonvoting equity security rsus plan performance share plan psp ne issue bearer form roche connect roche option plan httpswwwrochecomaboutgovernancearticleofincorporationhtmcorporate governance roche roche issue option apart employee option award employee stock option describe finance report debt instrument issue note roche group consolidated financial effect roche share capital statement equity compensation plan option issue connection debt instrument board director corporate executive committee information member board exception dr severin schwan director member corporate member board director office executive committee list page end member roches corporate member board director age limit executive committee serve executive restriction term office capacity group subsidiary financial year preceede current reporting curricula vitae cvs current period lack exist business member year body connection group subsidiary independent information include information roche board director independence definition year election additional position base definition swiss code good membership activity available practice corporate governance economiesuisse continuously update internet addition complement specific precede criterion status cvs body relevant httpswwwrochecomaboutgovernanceboard reporting date december ofdirectorshtm year separately available principle governance principle rule pursuant article para point vegv delegation competence reservation power number permit activity board management group company director corporate executive committee executive body company include economic member outline article environmental social topic principle incorporation roche hold ltd internal organisation board director division authority annual general meeting elect responsibility board management member board director chairman remits board committee board director member information control mechanism available remuneration committee annual basis board dealing corporate management election nominee vote separately govern bylaw article incorporation roche holding ltd minutes st annual board director roche holding ltd general meeting roche holding ltd hold organised ensure group conduct march business responsibly focus longterm httpswwwrochecomaboutgovernanceboardofdirectorshtm httpswwwrochecomaboutgovernanceexecutivecommitteehtm httpswwwrochecomaboutgovernancearticleofincorporationhtm httpswwwrochecomaboutgovernanceannualgeneralmeetingshtm httpswwwrochecomaboutgovernancearticleofincorporationhtm board director board committees board director chairman nomination committee board committees remuneration committee audit committee corporate governance sustainability committee corporate executive corporate executive committee committee value creation end roche board board director establish system delegate certain responsibility control continuously monitor committee composition chairperson audit committee corporate governance december describe sustainability committee board committee authority responsibilitie director consist follow element define detail bylaw board report operate financial risk risk director management system roche group establish risk management committee chair independent process cover entire company system director place identify manage type risk potentially affect business include economic according bylaw board director environmental social impact risk board meeting convene opportunity contain stakeholder input chairman present request board director high governance member roche board meet year body involve roche risk management policy set assess chairman performance meeting approach accompany responsibility attend chairman chair pharmaceutical diagnostic division vicechairman global function conduct formal risk assessment process year develop risk management information system plan material risk mis board director regularly inform monitored deviation review regular important issue sale performance performance dialogue consolidate group risk etc board access electronic information report include target risk profile discuss platform provide timely information corporate executive committee approve board director board committee group business plan material system control set forth risk review board yearly basis httpswwwrochecomaboutgovernancecommitteeshtm httpswwwrochecomaboutgovernancearticleofincorporationhtmcorporate governance roche effectiveness risk management process evaluate appropriateness completeness monitor group risk advisory team efficiency process control action plan overall process regularly review external implement necessary change enhancement auditor finding present audit develop businessauditee committee board detail risk track completion management include risk factor risk statutory auditor management policy risk management chief compliance officer compliance officer website financial risk management specifically subsidiary describe finance report safety health environmental protection system internal control financial reporting department page finance report corporate sustainability committee internal audit science ethic advisory group seag group audit report general counsel issue relate genetic genetic engineering direct access give regular briefing audit committee corporate governance member corporate executive committee sustainability committee ongoing activity invite attend meeting board director audit report chief audit risk advisory report person agenda item executive attend audit committee partly concern situation warrant corporate governance sustainability member enlarge corporate executive committee meeting external auditor committee invite attend board group audit independent appraisal function committee invite chairman board evaluate review group activitie corporate executive committee member deliver service board director report committee meeting elect management annual audit plan yearly commission independent expert report define focus area eg market access thirdparty service consultant management validate senior management present audit committee roche year blackout period impose group commit maintain high standard member board director internal control worldwide senior employee prohibit trading operation management responsible assess company stock follow blackout period business risk aspect operation effect implement effective efficient process december january control whilst ensure compliance internal april april external rule regulations june july conduct operational audits group audit october october determine management response risk blackout period change chairman surround business process system board director circumstance warrant httpswwwrochecomsustainabilityapproachriskmanagementhtm additional information provide finance report note roche group consolidate financial statement risk management httpswwwrochecomsustainabilityenvironmenthtm httpswwwrochecomsustainabilityhtm httpswwwrochecomresearchanddevelopmentwhowearehowweworkethicsinrdethicalconflictshtm dr andreas oeri chairman corporate governance sustainability committee board director meet meeting board director regularly conduct generally hour length include assessment selfassessmentassessment fullday meeting addition day visit party electronical survey personal major subsidiary interview performance board committee meet follow member corporate executive committee chairmansnomination committee approx maximum ordinary notice period hour month changeofcontrol clause remuneration committee meeting approx employment contract hour audit committee meeting approx hour management contract fall scope subsection annex corporate governance sustainability directive information relate corporate committee meeting approx hour governance remuneration committee member recuse deliberation decision matter affect interest figure indicate actual length meeting include director extensive premeete preparation postmeete followup activitiescorporate governance roche attendance board board committee meeting corporate chairmans governance nomination remuneration audit sustainability board committee committee committee committee number meeting c franz hoffmann j bell j brown p bulcke h clevers member board march hauser rp lifton oeri b poussot schwan c suessmuth dyckerhoff p r voser member board june member committee member march member march member june remuneration shareholding loan detail remuneration shareholding rule aol loan content method determine content board cec compensation shareholding programme rule principle basic principle element compensation applicable performance shareholding programme serve related pay member board director corporate rule principle executive committee description allocation equity security authority procedure determine convertible right option set forth separate remuneration report additional payment page finance report member executive note roche group consolidated committee appoint financial statement equity attributable roche vote pay general shareholder relate party page meet shareholder list note financial statement rule loan credit facility roche holding ltd board executive postemployment benefit shareholding rule vote pay agm follow rule remuneration shareholding loan board director board corporate executive committee cec set forth article incorporation aoi httpswwwrochecomaboutgovernancearticleofincorporationhtm participatory right shareholders participatory right shareholder define article incorporation roche article incorporation roche shareholder represent share nominal value share issue bearer restriction chf million request placement admission annual general meeting item agenda annual general meeting exception share deposit later day specify period date meeting date meeting admittance card issue shareholder provide article rule issue instruction incorporation shareholder elect independent proxy rule electronic represent party annual general participation annual general meeting lay meeting correspond invitation annual general meeting regulate article article incorporation contain restriction incorporation exercise voting right quorum requirement stipulate conformity swiss code obligation change control defensive measure article incorporation contain provision terminate event acquisition mandatory bid rule swiss law apply vest period restriction preexist award remove option changeofcontrol clause exercise immediately component remuneration base roche ne relationship statutory auditor annual general meeting roche holding ltd serve capacity provide march shareholder voted appoint statutory auditor participate kpmg ag kpmg statutory auditor audit committee meeting prepare write oral report result audits base exist legal requirement swiss audit committee oversee assess auditor code obligation article concern make recommendation board maximum term office seven year auditor information authority responsibility charge ian starkey auditorincharge audit committee article business year replace mark baillache bylaw statutory auditor participate start business year information meeting audit committee long auditor auditorincharge httpswwwrochecomaboutgovernancearticleofincorporationhtm httpswwwrochecomaboutgovernancearticleofincorporationhtmcorporate governance roche performance kpmg assess base audit fee review head group audit different element affiliate survey evaluate approve audit committee year service level country level interview take consideration change roche business roche key stakeholder selfevaluation change financial reporting audit kpmg internal process ensure compliance standard regulation federal audit oversight authority faoa audit committee guide statutory auditor elect year annual general meeting kpmgs independence ensure limit kpmg provide certain nonauditing service auditing service provide legally require furthermore permit service exceed total audit fee auditor direct auditrelated service include assurance access audit committee chair accounting service provide auditor head group audit discuss relevant issue necessarily provide statutory auditor service legal requirement report statutory auditor include attestation service comfort consolidated financial statement letter consent consultation financial statement find page respectively finance report tax service include service respect compliance tax return tax advice kpmg receive follow remuneration service relate audit tax service statutory auditor roche holding ltd auditor roche company service include advice relate process include chugai improvement regulation training company formal policy govern millions chf engagement statutory auditor nonaudit auditing services service policy prohibit certain service auditrelate service provide permit certain service assurance limit agree audit committee nonstatutory audits potential nonaudit service engagement review tax service policy authority proceed service give total relationship independent proxy recent year bdo ag serve independent compensation list jointstock company vegv proxy annual general meeting board director appoint testaris ag march shareholders elect bdo ag replacement independent proxy conclusion independent proxy period general meeting board director conclusion ordinary annual general nominates testaris ag election independent meeting shareholder bdo ag pay proxy general meeting period service annual general meeting conclusion ordinary accord expenditure totalling chf general meeting shareholder chf rule issue instruction bdo ag resignation july independent proxy rule electronic independent proxy elect general participation annual general meeting meeting view cease execution lay correspond invitation mandate independent proxy pursuant annual general meeting regulate article para ordinance excessive article incorporation information policy provide article incorporation analyst investor conference available corporate notice publish swiss official internet publication available gazette commerce daily newspaper httpswwwrochecompublicationshtm designate board director basler zeitung order email baselwarehouseservicesrochecom finanz und wirtschaft lagefi le temps neue fax zrcher zeitung contact address investor relation roche report halfyear fullyear result f hoffmannla roche ltd investor relation business report publish print andor online group finance basel switzerland format medium event addition detail tel firstquarter month sale figure fax publish year april october current list publication date available additional information include detail specific english german internet contact person available internet relevant information document include medium release investor update presentation httpswwwrochecomaboutgovernancearticleofincorporationhtm httpswwwrochecommediahtm httpswwwrochecominvestorshtm httpswwwrochecominvestorscontactshtmcorporate governance roche chief compliance officer compliance officer network chief compliance officer compliance addition roche establish business ethic officer network commit ensure incident report beir system enable roche group code conduct consistently chief compliance officer capture track comply roche group monitor allege violation initial report serve contact person shareholder local compliance officer resolution employee customer supplier general public issue relate implementation business ethic incident record system compliance code employee group internal investigation department party aware violation regionallocal management receive specific roche group code conduct bring concrete information allege violation attention manager supervisor roche group code conduct certain local compliance officer report chief predefine category corporate governance compliance officer ms pascale schmidt email sustainability committee audit pascaleschmidtrochecom tel committee board director inform disclosure treat confidentially substantial violation management corrective addition end employee action anonymously report irregularity complaint mother tongue speakup line start chief compliance officer report general december new compliance tool group counsel submit regular report level socalle roche group code conduct corporate governance sustainability committee help advice line introduce strive need audit committee board provide guidance case question uncertaintie director interpretation roche group code conduct reference document furthermore serve platform idea suggestion concern document nonapplicabilitynegative disclosure expressly note information negative declaration provide swis contain mention non exchange corporate governance directive applicable omission construe commentary thereto httpswwwrochecomaboutgovernancecodeofconducthtm httpswwwrochecomsustainabilityapproachhtmremuneration report roche remuneration report employee compensate fairly transparently competitively participate appropriately company success honour performance success optimal condition enable employee good possible contribution improve wellbee people need principle www roche innovative agile company base transparent compensation structure compensation success depend substantially expertise ensure compensation package competitive policy motivation performance employee structure individual component httpswwwroche conviction form basis compensation policy regularly benchmarke swiss european comcareersfor international criterion remuneration guideline employee roche aim remunerate employee fairly underlying principle subject rewardshtm transparently line market condition regular outside comparison enable participate appropriately sound value company success pursue goal provide compensation policy factor system competitive performancebased resultsoriente safeguard roche future success key httpswwwroche compensation element corporate culture offer employee comcareersfor condition good employeesliving strive balanced mix fix variable possible contribution share corporate goal ourvalueshtm compensation component gear employee improve healthcare patient include position management responsibility sound sustainabilityoriente value system base integrity courage passion firstly variable component intend create time decentralise management approach additional financial incentive achieve corporate play major role wide scope individual goal innovation consistently high decisionmake respectful interaction openness level increase value company diversity wideranging training development create stakeholder group secondly order opportunity attractive working environment allow employee manager participate unidimensional diminishment question company business success adequate compensation remuneration fall far short measure key objective incentivise annual bonus payment longterm security roche commit fair performancebase base programme resultsoriente compensation policy link employee interest global company like roche marketcompetitive stakeholder group remuneration play key role performanceremuneration report roche remuneration decision process approval framework overview company major swiss company year remuneration committee roche report finding board external board director decide remuneration board consulting firm pricewaterhousecooper pwc member member group corporate assist remuneration committee roche executive committee perform market comparison advise pwc award additional mandate chairman group ceo member roche group information remuneration group corporate executive committee committee remit power procedure present remuneration committee decide make remuneration decision find correspond compensation right bylaw roche board director decision decision right reserve article incorporation outline remuneration committee member section principle govern specific remuneration component remuneration committee track market datum salary lead global pharmaceutical remuneration decision process approval framework beneficiary remuneration board director bod corporate executive decision approval component chairman c committee cec incl ceo roche group base payremuneration bonus c stocksettle stock remuneration committee appreciation right ssar restrict stock unit rsus annual general performance share plan psp board director meet expiring plan recommendation psp remuneration committee psp end respectively decision pension c remuneration committee end new psp award board director determine payment grant performance share plan psp expire psp determine act recommendation payment psp end remuneration committee end respectively peer set abbott laboratories abbvie amgen astella astrazeneca bayer bristolmyers squibb eli lilly glaxosmithkline johnson johnson merck co novartis pfizer sanofi takeda change composition peer set compare abb credit suisse lafargeholcim nestl sonova straumann swis ubs zurich insurance httpswwwrochecomaboutgovernancearticleofincorporationhtm httpswwwrochecomaboutgovernancearticleofincorporationhtm total aggregate amount base general meeting shall vote annually decision submit general bind effect approval remuneration meeting approval implement ordinance board director resolve board excessive compensation list jointstock directors corporate executive committee company verordnung gegen bermssige verg tun detail gen bei brsenkotierten aktiengesellschaften vegv peer set abbott laboratories abbvie amgen astella astrazeneca abb bayer credit suisse bristolmyer squibb roche lafargeholcim eli lilly nestl glaxosmithkline sonova johnson johnson straumann merck co swiss novartis ubs pfizer zurich insurance sanofi takeda peer set market comparison company salary assessment pharma peer set major swiss company procedure submit total board retrospective approval executive remuneration shareholder approval total aggregate bonus amount corporate annual general meeting executive committee chairman board year annual general meeting agm director financial year end shareholder approve total remuneration submit retrospectively ordinary agm board director corporate executive separate bind approval committee decide board director remuneration committee board director prospective approval respectively board executive aggregate remuneration submit prospectively agm accord approval agm separate bind approval period roche commit obtain separate ordinary agm bind shareholder approval total remuneration pay board director corporate executive committee followsremuneration report roche andr hoffmann chairman remuneration committee peer set approval total remuneration annual general meeting agm financial year financial year retrospective c chairman bod c bonus bonus financial year total cec corporate executive committee cec include ceo roche group bonus bonus financial year total prospective bod board director bod include c base payremuneration aggregate total remuneration agm agm base payremuneration corporate executive committee cec include ceo roche group cec aggregate total remuneration agm agm base pay ssar base pay rsus stocksettle stock appreciation right ssar indirect benefit restrict stock unit rsus indirect benefit agm agm agm remuneration component overview remuneration element compose ssar rsus describe outlook base exist individual target value annual report start total lti corporate executive committee composition remuneration component member base pay measure longterm incentive lti corporate january year vest expiration period executive committee enlarge corporate align newly issue ssar rsus executive committee change unlike participant programme member corporate executive lti corporate executive committee committee choice determine mix enlarge corporate executive committee rsus ssar fouryear complement restrict stock unit rsus cliff vest corporate executive committee lti mix ssarsrsus fix base calculation vest period cliff vest expiration period base exist new year new year new year ssar individual target value year year year total lti corporate executive committee member rsus base pay measure new year new year january year remain participant ssar expiration period newly issue ssar rsus programme offer yearly basis extend currently seven year year choice combination determine mix give participant additional year restrict stock unit rsus stocksettle stock exercise vest ssar vest schedule appreciation right ssar option instead newly issue rsus change threeyear cliff ssar country follow option vest fouryear annual vesting year available grant rsus vest available participant vest schedule ssar choice choice choice currently threeyear annual vest align ssar ssar ssar fouryear annual vest schedule rsus rsus rsus new grant offer level choice empower participant change roche long term incentive engage fully total reward enable programme attractive enable roche attract well understand critical element motivate retain good talent align compensation increase value programme company longterm success position roche peer group provide benefitremuneration report roche remuneration remuneration component link member board director corporate employee performance company financial executive committee compose follow performance commercial success align element concrete composition chart interest roche employee composition remuneration board shareholder director corporate executive committee lti remuneration component intend fix base salary complement annual sustainably homogenously longterm variable bonus shortterm incentive sti orient perspective align management interest perennial remuneration element ssar rsus shareholder holder nonvoting longterm incentive lti equity security participate manager additional incentive achieve sustainable end new performance shareholder value growth share plan psp award grant act recommendation remuneration committee end board director determine payment expire psp determine payment psp end respectively composition remuneration board director corporate executive committee annual remuneration element description c bod ceo roche group cec base pay monthly payment q uarterly remuneration payment bonus annual payment year year cash block nonvoting block nonvoting equity security equity security andor share andor share pension etc perennial remuneration element stocksettle stock appreciation right ssar restrict stock unit rsus performance share year plan psp block nonvoting expiring plan equity security psp andor share psp variable longterm sti base salary bonus indirect benefit employer contribution lti pension insurance contribution stocksettle stock appreciation right roche roche connect restrict stock unit tax consulting service remuneration performance share plan component expense allowance children school cost foreign tax obligation ahvivalv fix base pay fix qualitative individual functional performance base pay cash payment determine objective competitive reason roche position base salary market datum lead disclose individual performance objective global pharmaceutical company footnote member corporate executive committee major swiss company footnote chairman reflect individual ability experience performance time pay adjustment likewise december end reporting year link individual performance january follow report year remuneration account prevail market condition committee decide bonus amount company overall financial situation payable chairman board members corporate executive committee respect remuneration committee make review current reporting year base performance final decision individual base pay pay aforementioned objective chairman board director member time remuneration committee decide corporate executive committee form bonus award ie cash payment remuneration member board andor nonvoting equity security andor share bonus variable remuneration committee use complete bonus annually award individual discretion weighting criterion contribution value creation business year bonus allocation mean incentive strive outstanding result create new business opportunity stocksettle stock appreciation right bonus amount link group divisional ssar longterm core profit sale growth constant exchange rate ssar proportion lti operating profit capital charge opac base corporate executive committee compose core operating profit core earning share base exist individual target value nonvoting equity security ne growth constant total lti corporate executive committee exchange rate product development pipeline member base pay measure diversity employee manager environmental january year goal achievement measurable andremuneration report roche ssar entitle holder benefit financially performance share plan psp longterm increase value roche nonvoting equity psp establish period security grant date exercise year base threeyear comparison date ssar grant vest total shareholder return tsr peer year exercise company footnote respective year year grant date unexercised ssar lapse psp consist overlapping performance compensation fair value cycle new cycle start begin ssar calculate grant date year cycle finishing end year trinomial model american option detail plan key performance metric award tsr calculate threemonth move average rate start end ssar corporate executive committee performance cycle allocate individually remuneration committee discretion total new psp award grant end employee receive ssar overlap performance cycle psp restrict stock unit rsus longterm psp psp close proportion restrict stock unit december rsus member corporate executive committee total lti base board director act recommendation exist individual target value total remuneration committee determine lti corporate executive committee member payment ongoing psp end base pay measure january complete discretion year rsu award allocate individually corporate executive committee remuneration indirect benefit committee discretion show ceo roche group chairman respectively member rsus contain right receive nonvoting equity corporate executive committee additionally securitie andor share newly receive indirect benefit payment pension fund define fouryear vest period plus value insurance roche connect payment foreign adjustment equivalent tax obligation tax consulting service annual sum dividend pay vest period expense allowance show individual attributable number nonvoting equity member corporate executive committee security andor share individual award receive payment family child education grant vested recipient allowance schooling cost child corporate executive committee year result nonvoting equity security andor share remain block year rsus serve remuneration component eligible roche employee weight fixedvariable longterm remuneration component target percentage total remuneration chairman board director corporate executive committee include ceo roche group fix variable longterm variable longterm remuneration pay member corporate executive committee range fix compensation ratio variable remuneration component relative fix base pay corporate executive committee ratio variable remuneration component bonus ssar rsus relative value fix base pay lti longterm sti variable total criterion bonus ssar total lti rsus total lti individual target value minimum maximum performance criterion group objective group divisional value development determine value development determine business performance individual performance ne performance plus value objective consider core profit grant adjustment dividend sale growth constant exchange ne grant rate operate profit capital charge opac base core operating profit core earning share nonvoting equity security ne growth constant exchange rate product development pipeline diversity employee manager environmental goal split group objective na na b individual objective na na weighting criterion complete discretion remunertion committee decision objective na applicable assess consideration performance competitor macroeconomic development b ase exist individual target value total lti corporate executive committee member base pay measure january year detail refer follow section remuneration report finance report note roche group consolidate financial statement relate party note financial statement roche holding ltd board executive shareholding remuneration report roche remuneration board director resolution approval director table board remuneration chairman board activity roche pay legally require employer director member board director contribution total chf swiss social decide remuneration committee security programme provide retirement disability discretion take account market comparison unemployment benefit ahvivalv member board director legally remuneration form cash payment require contribution separately state annually track market datum director chairman board director pay lead global pharmaceutical company footnote major swiss company basic remuneration board director footnote assist consultancy exclude chairman remain unchanged pwc previous year board exception chairman board director separately submit total aggregate director bonus form block share bonus chairman board directors dr severin schwan executive member general meeting financial year board member board director retrospectively bind approval award share nonvoting equity security ssar maximum amount total aggregate remuneration board director period loan credit grant member ordinary general meeting board director ordinary general meeting separately table previous year general capacity member chugai meeting prospectively bind approval international council cic chugai pharmaceutical co ltd andr hoffmann receive honoraria remuneration member amount total usd chf board director member board director advisory service genentech scientific receive remuneration additional compensation review board prof dr richard p lifton receive form quarterly fix cash payment show honoraria amount total usd remuneration member board chf list member position committee membership chairmanship detidua remuneration member board director chf additional remuneration additional special basic remuneration committee memberschair remuneration total remuneration c franz chairman total remuneration pay chairman board director hoffmann vicechairman j bell j brown p bulcke h clevers march hauser rp lifton oeri b poussot schwan high total remuneration pay dr severin schwan member corporate executive committee remuneration receive primary function ceo roche group reflect total remuneration corporate executive committee c suessmuth dyckerhoff pr voser end june total exception member chairmans committee chairman vicechairman board member receive chf year committee serve chf year committee chair remuneration serve vicechairman board prorate remuneration period march december prorate remuneration period january end june additionally employer contribution ahvivalv totalling chf include chairman pay form remuneration detiduaremuneration report roche remuneration member board director chf additional remuneration additional special basic remuneration committee memberschair remuneration total remuneration c franz chairman total remuneration pay chairman board director hoffmann vicechairman j bell j brown p bulcke hauser rp lifton oeri b poussot schwan high total remuneration pay dr severin schwan member corporate executive committee remuneration receive primary function ceo roche group reflect total remuneration corporate executive committee c suessmuth dyckerhoff pr voser total w ith exception member chairmans committee chairman vicechairman board member receive chf year committee serve chf year committee chair remuneration serve vicechairman board additionally employer contribution ahvivalv totalling chf include chairman pay form remuneration total remuneration pay chairman form share block year payable board director march shareholder bind vote chairman dr christoph franz receive total ordinary annual general meeting agm remuneration show remuneration committee bonus proposal adopt chairman total remuneration contain late respect financial year total remuneration board director total remuneration pay chairman board director chf base salary cash bonus subject approval annual general meeting pension fundsmgb insurancesannual expense allowance total form share block year calculation number share base price date transfer march respectively approval agm agm respectively calculation value consideration reduction value block period year reduce market value submit shareholder approval agm approve agm respectively nclude employer contribution social security beneficial part mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitshare foundation supplement occupational pension benefit dissolve dditionally employer contribution ahvivalv chf chf pay form remuneration detidua detidua total remuneration pay board board remuneration subject approval director annual general meeting calendar year member board director receive remuneration include submission chairman total aggregate bonus employer contribution social bonus bind vote annual general security beneficial part totalling chf meeting chf exclude additional remuneration chairman board employer contribution pay ahvivalv director include bonus award chf totalling chf chf form share block year show form remuneration table section total remuneration pay chairman board director board remuneration pay member director submit remuneration committee board director bonus proposal adopt late member board director dr franz chairman board dr christoph franz b humer receive fee amount total respect financial year payable march usd chf serve member exclude legally require employer chugai international council cic chugai contribution ahvivalv shareholder pharmaceutical co ltd bind vote ordinary annual general meeting member board director william burns receive honoraria amount total usd chf capacity member chugai international council cic chugai pharmaceutical co ltd additional remuneration pay retrospective approval chairman total aggregate bonus chf proposal agm agm agm aggregate aggregate aggregate financial year financial year financial year total aggregate proposal approval approve agm exclude legally require employer contribution ahvivalv bonus award form share block year calculation number share base price date transfer march march april respectively approval agm agm agm respectively calculation value consideration reduction value block period year reduce market value submit shareholder approval agm approve agm agm respectively detiduaremuneration report roche submission board total aggregate dr severin schwans remuneration show future remuneration bind shareholder vote receive function ceo roche board director propose group member corporate executive ordinary agm approve board remuneration totalling committee include chf exclude legally corporate executive committee total remuneration require employer contribution ahvivalv exclude bonus period end ordinary agm prospective approval board total aggregate future remuneration chf proposal agm agm agm aggregate aggregate aggregate period period period agm agm agm agm agm agm total aggregate proposal approval approve agm exclude legally require employer contribution ahvivalv exclude bonus reconciliation report remuneration comparison ordinary agm shareholder approve remuneration ordinary agm actual remuneration amount member board director chf exclude legally require employer ordinary agm approve board remuneration contribution ahvivalv exclude bonus total chf exclude legally require employer contribution ahviv alv exclude bonus period end ordinary agm prospectively approve total remuneration member board director comparison actual total payment chf total remuneration total remuneration total remuneration period period period agm agm agm agm agm agm maximum total remuneration approve agm actual total remuneration pay calculation end period approve limit calculation end period yes yes exclude legally require employer contribution ahvivalv exclude bonus security holding relate party note director andr hoffmann dr andreas oeri financial statement roche holding ltd member founder family closely significant shareholder addition associate belong contractually bind december december shareholder group pool voting right respectively member board director end group hold share person closely associate hold roche issue share detailed information share nonvoting equity security nes group find finance report note american depositary receipt adrs show roche group consolidated financial statement table security holding security holding share nes december december nonvoting nonvoting equity close relative equity close relative security security security security share ne holding share ne holding number number numbertype number number number numbertype number board director c franz hoffmann j bell j brown p bulcke h clever na na na na hauser ne nes rp lifton adr adr oeri b poussot schwan security holding security holding corporate executive committee corporate executive committee c suessmuth dyckerhoff total ne adr ne adr na applicable share hold shareholder group pool voting right list jointly hold close relative roche adr american depositary receipt list otcqx httpswwwotcmarketscomstockrhhbyquote international premier symbol rhhby isin trade usd adr represent underlying nesremuneration report roche remuneration corporate executive committee resolution approval member corporate executive remuneration member corporate committee receive remuneration work executive committee decide show remuneration remuneration committee discretion take ceo roche group dr severin schwan account market comparison explain detail previous year board payment daniel oday retire director separately submit total aggregate corporate executive committee end bonus corporate executive committee december roche end general meeting financial year february included aggregate retrospectively bind approval total remuneration corporate executive committee maximum amount total aggregate remuneration corporate executive committee payment dr michael heuer ceo roche period ordinary general meeting diagnostic retire member ordinary general meeting corporate executive committee retire table previous year general roche july include aggregate meeting prospectively bind approval total remuneration corporate executive committee remuneration member corporate executive committee individually specify remuneration dr thomas general provision assign authority decision schinecker include payment corporate executive committee remuneration role payment member corporate remuneration committee board executive committee august director outline remuneration decision process approval framework high total remuneration pay dr severin schwan member corporate executive committee chf base salary ssar pension fundsmgb insurance roche connect bonus subject approval total aggregate bonus corporate executive committee annual general meeting block share rsus na psp na payment incl expense allowancefor tax consulting service total na applicable calculation value nonvoting equity securitiesshare consideration reduction value block period year reduce market value include employer contribution social security beneficial part detailed calculation remuneration annual report number ssar grant value accord trinomial model american option chf trinomial model american option value describe stocksettle stock appreciation right ssar member corporate executive committee ssar block year exercise whilst exercise result ne automatically block additional year calculation value nonvoting equity security consideration reduction value additional block period year reduce market value number ssar grant value accord trinomial model american option chf trinomial model american option value describe stocksettle stock appreciation right ssar member corporate executive committee mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitshare foundation supplement occupational pension benefit dissolve hare block year calculation number share base share price date transfer march approval agm c alculation rsus value number rsus multiply grant value chf ne closing price grant date march rsu arget number nonvoting equity security psp nonvoting equity security multiply nonvoting equity security price average month october december prior start performance cycle chf nonvoting equity security include annual expense allowance chf payment tax consulting service chf chf family child education allowance chf anniversary payment chf additionally employer contribution ahvivalv chf chf pay form remuneration detidua high total remuneration pay high total remuneration pay member dr severin schwan member corporate corporate executive committee executive committee include total pay corporate dr severin schwan executive member board executive committee total remuneration director receive remuneration primary pay member corporate executive function ceo roche group reflect committee remuneration report roche allocation dr michael heuer bonus chf propose include aggregate total remuneration corporate executive committee total aggregate bonus bring forward bind vote annual general meeting daniel oday receive bonus payment dr severin schwan members corporate executive committee receive bonus cash payment march dr severin schwan receive bonus form roche share block year bonus payment march bonus chf subject approval total aggregate bonus corporate executive committee annual general meeting b anderson na hippe g keller schinecker na c wilbur total na applicable detidua base pay member corporate executive committee base pay chf b anderson na hippe g keller schinecker na c wilbur total na applicable detidua payment daniel oday dr michael heuer retirement roche end february july respectively include aggregate total remuneration corporate executive committee bonus member corporate executive committee remuneration committee board director determine corporate executive committee member bonuse base performance agree objective remuneration committee use complete discretion weighting criterion bonus detidua stocksettle stock appreciation right total lti corporate executive committee ssar member corporate member base pay measured executive committee january year ssar corporate executive committee allocate individually remuneration fair value ssar calculate grant committee discretion ssar show date trinomial model american ssar table entitle holder option trinomial model effective method benefit financially increase value valuation american option consider roche nonvoting equity security nes possibility exercise option time prior grant date exercise date strike price maturity call american option compare ssar term multiyear plan european option allow exercise closing price roche ne grant date maturity date ssar vest previously grant ssar year grant date vest number ssar strike price expiry date ssar exercise convert ne grant value ssar show previously grant ssar seven year ssar table number ssar grant date unexercised ssar lapse calculated time issue enter compensation value table ssar proportion lti ssar grant daniel oday corporate executive committee compose dr michael heuer base exist individual target value stocksettle stock appreciation right ssar chf ssar ssar b anderson na hippe g keller schinecker na c wilbur total na applicable information trinomial model american option refer boyle phelim p lattice framework option price state variable journal financial quantitative analysis volume issue mar httpswwwrochecomdam jcraaacbfabcbeacentrinomialmodelpdf strike price table ssar remuneration report roche restrict stock unit rsus define fouryear vest period plus value member corporate executive committee adjustment equivalent proportion restrict stock unit sum dividend pay vest period rsus member corporate executive attributable number nonvoting equity committee compose total lti security andor shares individual award base exist individual target value grant vested recipient total lti corporate executive committee corporate executive committee member base pay measure year result nonvoting equity january year rsu award allocate security andor share remain block individually corporate executive committee year remuneration committee discretion daniel oday dr michael heuer rsus contain right receive nonvoting equity receive rsus security andor share newly restrict stock unit rsus number value grant chf value chf b anderson hippe g keller schinecker c wilbur total na applicable calculation value consideration reduction value additional block period year reduce market value c alculation value consideration reduction value additional block period year reduce market value performance share plan psp end new psp award member corporate executive committee grant psp establish period overlap performance cycle psp year base threeyear comparison psp psp close total shareholder return tsr peer december board director act company footnote respective year recommendation remuneration psp consist overlapping performance committee determine payment cycle new cycle starting begin ongoing psp end year cycle finishing end year complete discretion plan key performance metric award tsr calculate threemonth move average provision plan number rate start end nonvoting equity security nes share performance cycle reserve participant cycle detidua number security actually award award grant require roche depend extent investment security perform well roche security share ne outperform peer set event investment average return investment security issue roche security underperform average return set peer company comparison base deliver peer company few ne security market price dividend yield share award ie total shareholder return tsr reduce effect shortterm market fluctuation security end psp cycle base price average month october threemonth average distribute dividend december prior start performance cycle totalling chf billion chf billion month october december chf billion chf billion end cycle accord term plan participant receive originally target ne award roche security perform well average end psp cycle ne peer set board director elect originally target ne incl ne increase ne share award maximum group ceo outline page award double originallevel reserve target annual report take account retire number ne share accord psp plus member corporate executive committee value adjustment equivalent award sum dividend pay vest period attributable number nonvoting bill anderson dr thomas schinecker dr michael equity securities share individual heuer participate psp programme performance share plan psp fair value grant nonvoting equity security ne ne price average month october december target number nonvote prior start fair value target number equity security ne performance cycle nonvoting equity security psp psp ne psp number value chf value chf hippe ga keller share c wilbur nes reserve total psp calculation value nonvoting equity security consideration reduction value block period year reduce market value ee footnote remuneration report roche detidua detidua indirect benefit employer contribution chf payment pension payment pension annual taxtax fund annual taxtax fund expense roche consulting mgb expense roche consulting insurance allowance connect service insurance allowance connect service b anderson na na na na hippe g keller schinecker na na na na c wilbur total na applicable include employer contribution social security beneficial part mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitshare foundation supplement occupational pension benefit dissolve remuneration loan member loan credit grant corporate executive committee member corporate executive committee base legal contractual obligation roche pay individual member corporate maximum regular period notice member executive committee cost respect temporary corporate executive committee month relocation housing family child changeofcontrol clause education allowance children school employment contract cost total chf aforementione additional payment include total remuneration member corporate executive committee detidua indirect benefit member addition member corporate executive corporate executive committee committee receive annual expense allowance employer contribution social security member payment foreign tax obligation scheme pension plan groupwide employee tax consulting service show table stock purchase plan roche connect respect member corporate executive committee show indirect benefit employer contribution payment employer contibution indirect benefit table table daniel oday dr michael heuer retirement roche end february roche connect voluntary stock purchase plan july respectively include aggregate offer employee opportunity buy roche total remuneration corporate executive nonvoting equity security nes committee equal annual salary discount ne purchase plan subject hold period year switzerland remuneration member chf chf corporate executive committee form remuneration pension totalling chf chf pay corporate additional remuneration executive committee member pension mention payment pay current benefit guarantee member corporate executive committee member executive committee widow outside pension fund pledge executive remuneration subject approval gap pension provision result annual general meeting posting abroad instance transfer roche pension fund require oneoff submission executive total aggregate transfer chf pension fund bonus bind vote annual general meeting total remuneration pay member board director propose award member corporate executive committee corporate executive committee bonus calendar year member dr severin schwan form roche share corporate executive committee receive remuneration block year member include bonus employer contribution corporate executive committee cash social security beneficial part payment payment totalling chf respect dr michael heuer ceo roche diagnostic financial year chf retirement end july payment exclude legally require employer contribution daniel oday retirement roche ahvivalv submit propose total end february totalling chf ordinary annual general meeting exclude additional employer agm bind vote contribution pay ahvivalv totalling retrospective approval member executive committee total aggregate bonus chf proposal agm agm agm aggregate aggregate aggregate financial year financial year financial year total aggregate proposal approval approve agm exclude legally require employer contribution ahvivalv detidua detidua detiduaremuneration report roche submission executive total future aggregate incentive ssar calculate grant value remuneration bind shareholder vote consider reduction value block board director propose period applicable rsus calculate ordinary agm approve remuneration time reservation nonvoting equity security corporate executive committee totalling share consider reduction value chf exclude legally require block period contribution pension benefit employer contribution ahvivalv exclude legally require employer contribution exclude bonus period end ahvivalv contribution expense ordinary agm payment foreign tax obligation tax consulting service roche connect executive total future aggregate remuneration compose base pay longterm prospective approval member executive committee total future aggregate remuneration chf proposal agm agm agm aggregate aggregate aggregate period period period agm agm agm agm agm agm total aggregate proposal approval approve agm exclude legally require employer contribution ahvivalv exclude bonus reconciliation report remuneration exclude bonus period end shareholder prospectively approve ordinary agm remuneration member corporate executive committee comparison ordinary agm ordinary agm approve remuneration ordinary agm remuneration amount corporate executive committee totalling chf exclude legally require employer chf exclude legally require contribution ahvivalv exclude bonus employer contribution ahvivalv psp assumption maximum value prospectively approve total remuneration member executive committee comparison actual total remuneration effect chf period period period agm agm agm agm agm agm maximum total remuneration prospectively approve agm total remuneration calculate end calculation end corresponding agmagm period period agm agm actual total remuneration realise corresponding agmagm period base actual calculate restrospectively calculation end correspond psp cycle calculation end end end grant value rsus period agm agm psp cycle approve limit calculation end period calculation end period yes additional pay new member corporate executive committee approval agm approved total exclude legally require employer contribution ahvivalv exclude bonus nclude assumption maximum possible award sharesnonvote equity security correspond psp cycle ue award ne psp cycle originally include calculation maximum possible award total remuneration period agm agm reduce chf clawback activity lead disciplinary action addition applicable statutory provision roche repeat willful failure perform duty longterm incentive plan include option reasonably assign roche partially reclaim distribute compensation result violation law public regulation special circumstance clawback commission crime gross negligence willful misconduct employee voluntarily serve notice employment termination employment ssar engage conduct bring disgrace disrepute rsus unvested date roche andor subsidiary termination employment lapse immediately violation roche directive guideline compensation relate business conduct termination employment result accord regulation psp programme misconduct ssar rsus grant originally target award ne share outstanding vest unvested shall lapse shall lapse compensation notice immediately compensation accord termination employment give reason ssar plan rule misconduct redundancy disability retirement participant include inter aliaremuneration report roche guideline security holding long serve corporate executive board director decide ceo committee exception bill anderson roche group members corporate dr thomas schinecker join corporate executive committee acquire share andor executive committee fulfil ne equivalent annual base salary ceo requirement end member roche group equivalent annual base corporate executive committee fulfil salarie annual base salary respectively requirement end retain holding type security value acquire ceo roche group share andor nes annual base salary member corporate executive committee share andor nes annual base salary security holding december december respectively member corporate executive committee person closely associate hold security show follow table share nonvoting equity security ne ssar share nonvoting equity security nes december december close relative close relative share ne security holding share ne security holding number number numbertype number number numbertype corporate executive committee share ne share nes schwan b anderson na na na na hippe ga keller schinecker na na na na c wilbur total na applicable ssar number ssar hold december corporate executive committee schwan b anderson hippe g keller schinecker wilbur total price chf market price ne december chf expiry date grant value ssar chf trinomial model american option v alue accord correspond annual report restrict stock unit rsus number rsus hold december corporate executive committee schwan na na b anderson hippe na na g keller na na schinecker c wilbur na na total grant value rsu chf chf chf ne closing price grant ne closing price grant ne closing price grant date march date march date march statutory auditor report roche general meeting roche holding ltd basel audit accompany remuneration audit involve perform procedure obtain audit report roche holding ltd year end evidence disclosure remuneration december audit limited report regard compensation loan credit information accord article accordance article ordinance ordinance excessive compensation list procedure select depend auditor jointstock company ordinance contain judgement include assessment risk section mark audit grey line include material misstatement remuneration report respective footnote page fraud error audit include remuneration report evaluate reasonableness method apply value component remuneration assess overall presentation remuneration responsibility board director report board director responsible preparation overall fair presentation believe audit evidence obtain remuneration report accordance swiss law sufficient appropriate provide basis ordinance board director opinion responsible designing remuneration system define individual remuneration package opinion opinion remuneration report year auditor responsibility end december roche holding ltd responsibility express opinion complie swiss law article accompany remuneration report conduct ordinance audit accordance swiss auditing standard standard require comply ethical requirement plan perform audit obtain reasonable assurance remuneration report comply swiss law article ordinance kpmg ag mark baillache marc ziegler license audit expert license audit expert auditor charge basel january kpmg ag viaduktstrasse po box ch basel kpmg ag subsidiary kpmg holding ag member kpmg network independent firm affiliate kpmg international cooperative kpmg international swiss legal entity right reserve independent assurance report nonfinancial report corporate governance sustainability committee roche holding ag basel engage perform assurance procedure provide roche group internal nonfinancial reporting guideline base assurance aspect nonfinancial report responsible care health safety environmental roche holding ag basel consolidated subsidiary protection report guideline publish european roche include annual report report chemical industry council cefic gri standard publish october global reporting initiative gri scope subject matter roche group internal corporate reporting manual assurance engagement reasonable limited level sustainability report guidanceeconomic performance assurance focus datum information year ended issue june december disclose report roche roche materiality determination process group level base gri standard publish october global carry work datum report prior report initiative gri reporting period respect projection target define guideline payment donation people contribution key figure sustainability risk reasonable assurance opportunity internally gather collate aggregated follow datum information publish report scope reasonable assurance engagement inherent limitation key figure relate grant donation patient accuracy completeness nonfinancial indicator organisation grant donation healthcare organisation subject inherent limitation give nature method sponsorship healthcare patient organisation determine calculate estimate datum assurance material aspect disclose report report read connection roche contribution key figure guideline definition procedure nonfinancial reporting management reporting process respect performance contribution key figure relate control environment relation datum aggregation contribution key roche responsibility figure roche corporate governance sustainability committee responsible subject matter criterion limited assurance selection preparation presentation select information follow datum information publish report accordance criterion responsibility include scope limited assurance engagement design implementation maintenance relate internal control materiality determination process roche group level relevant reporting process free material according requirement gri standard misstatement fraud error disclose report design sustainability risk opportunitie responsibility determination process base roche group level activity responsibility perform limited reasonable assurance disclose paragraph risk management engagement express conclusion aspect report nonfinancial reporting roche plan perform people key figure disclose page report procedure accordance international standard safety security health environmental protection assurance engagement isae revise assurance key figure include greenhouse gas emission engagement audits review historical financial scope scope result business flight information respect greenhouse gas emission table graph page report international standard assurance engagement isae figure roche group level relation payment assurance engagement greenhouse gas statement issue donation disclose report international auditing assurance standard board management reporting process respect people standard require plan perform assurance payment donation key figure relate engagement obtain limited reasonable assurance control environment relation datum aggregation identify nonfinancial information prepare material aspect key figure accordance roche policy procedure management reporting process relate criterion control environment relation datum aggregation exist management reporting process respect non design form appropriate basis report financial reporting key figure prepare roche base fair picture nonfinancial performance roche policy procedure set forth follow roche group guideline grant donation sponsorship limited assurance engagement substantially scope gsd data collection process disclose website reasonable assurance engagement relation pricewaterhousecoopers ag birchstrasse postfach ch zurich telephone telefax wwwpwcch pricewaterhousecoopers ag member global pricewaterhousecooper network firm separate independent legal entityindependent assurance report roche risk assessment procedure include understand internal key organisational value objective report prioritisation control procedure perform response assess material aspect risk consequently nature timing extent procedure inspect integration sustainability risk gather sufficient appropriate evidence deliberately limit opportunity group risk management process relative reasonable assurance engagement adherence internal guideline assurance obtain limited assurance engagement assessment process data consolidation reasonable assurance engagement procedure select review management nonfinancial reporting process depend assurance practitioner judgement payment donation contribution people key figure independence quality control assess aggregation process datum roche group level comply independence ethical requirement code ethic professional accountant conduct work datum outline issue international ethic standard board accountant subject matter define believe evidence found fundamental principle integrity objectivity obtain sufficient appropriate provide basis professional competence care confidentiality assurance conclusion professional behaviour reasonable assurance conclusion firm apply international standard quality control base work perform opinion follow apply accordingly maintain comprehensive system quality control material aspect include document policy procedure compliance contribution key figure describe scope ethical requirement professional standard applicable subject matter section material aspect state legal regulatory requirement accordance report criterion b management reporting process respect summary work perform contribution key figure control environment assurance procedure include follow relation datum aggregation contribution key work figure work design provide appropriate review application roche group guideline basis report review application roche group nonfinancial c contribution key figure fair picture non report contribution guideline financial performance roche site visit management inquiry visit select site roche pharmaceuticals limited assurance conclusion diagnostic division usa norway china hong kong base work perform come attention selection base quantitative qualitative criterion cause believe material aspect interview personnel responsible internal nonfinancial roche materiality determination process group level report datum collection site visit disclose adhere principle guide roche group level determine understand application factor eg soundness stakeholder determination peer roche nonfinancial contribution guideline review relevance regulatory environment integration assessment key figure key organisational value objective define perform test sample basis evidence support gri standard select payment donation contribution people design sustainability risk opportunitie key figure eg roche accident rate energy consumption determination process group level disclose emission air water usage discharge grant donation function design patient organisation employee engagement rate woman key figure mention scope subject matter key leadership role concern completeness accuracy section disclose nonfinancial reporting adequacy consistency roche annual report state accordance review documentation analysis relevant policy report criterion principle management reporting process collect review relevant documentation sample basis include aggregate payment donation people key roche group nonfinancial reporting policy management figure control environment relation reporting structure documentation datum aggregation work exist design review principle roche materiality process provide definition development adherence pricewaterhousecoopers ag gris environmental social economic reporting requirement address soundness identification process christophe bourgoin fabienne fricker determination impact stakeholder peer competition review integration relevant regulatory requirement integration zurich january key date publish f hoffmannla roche ltd annual general meeting group communications march basel switzerland tel firstquarter sale wwwrochecom april orderdownload publication halfyear result internet rochecompublication july email baselwarehouseservicesrochecom fax ninemonth sale october medium relation tel email mediarelationsrochecom investor relation tel email investorrelationsrochecom corporate sustainability committee tel email corporatesustainabilityrochecomimprint roche cautionary statement forwardlooke statement earning share growth statement profit forecast interpret annual report contain certain forwardlooke mean roche earning earning share statement forwardlooke statement subsequent period necessarily identify word believe expect match exceed historical publish earning anticipate project intends seek earning share roche estimate future similar expression discussion thing strategy goal trademark legally protect plan intention factor cause actual result differ materially future link thirdparty page provide convenience reflect forwardlooke statement contain express opinion content annual report pricing product thirdparty page expressly disclaim initiative competitor legislative regulatory liability thirdparty information use development economic condition delay thereof inability obtain regulatory approval bring product market fluctuation currency roche annual report publish german exchange rate general financial market english condition uncertaintie discovery development marketing new product new reporting consist actual annual report use exist product include limitation finance report contain annual negative result clinical trial research project financial statement consolidate financial unexpected effect pipeline market statement regard content management product increase government pricing pressure report article incorporation consist interruption production loss inability aforementione report exception obtain adequate protection intellectual property remuneration report right litigation loss key executive employee adverse publicity print nonchlorine bleach fsccertified paper news coverageour image video f hoffmannla roche ltd basel switzerland like immediately experience patient story word free xtend app trademark legally protect open scan option app look icon watch video wwwrochecom ios android